U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-KSB
ANNUAL REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the Fiscal Year Ended December 31, 1997 Commission File Number: 0-18109
Exact name of small business issuer as specified in its charter
BCAM INTERNATIONAL, INC.
State or other jurisdiction of IRS Employer
incorporation or organization: New York Identification No.: 13-3228375
Address of principal executive offices:
1800 Walt Whitman Road,
Melville, New York 11747
(516) 752-3550
Securities registered under Section Name of each exchange on which
12(b) of the Exchange Act: registered:
Common Stock, $.01 par value Boston Stock Exchange
NASDAQ SmallCap
Securities registered under Section 12(g) of the Exchange Act:
Common Stock, $.01 par value
Common Stock Purchase Warrants
Units consisting of three common shares and
two redeemable Class A Warrants
Check whether the registrant (1) filed all reports to be filed by Section
13 or 15 (d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes X No __
Check if disclosure of delinquent filers in response to Item 405 of
Regulation S-B is not contained in this form, and no disclosure will be
contained, to the best of the registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB [ ].
Registrant's revenues for its most recent fiscal year were $3,959,000.
The aggregate market value of the registrant's common stock held by
non-affiliates as of April 9, 1998, was approximately $19,431,000 based on the
average closing price of such stock on April 9, 1998, as reported by NASDAQ.
The number of shares outstanding of the registrant's common stock as of
April 9, 1998, was 18,575,044.
DOCUMENTS INCORPORATED BY REFERENCE
None.
Transitional Small Business Disclosure Format (check one): Yes |_|; No |X|
<PAGE>
PART I
ITEM 1. DESCRIPTION OF BUSINESS
BCAM International Inc. (formerly Biomechanics Corporation of America prior to a
name change effected June 22, 1995), was organized in 1984 under the laws of the
State of New York.
GENERAL
BCAM International, Inc. and subsidiaries (the "Company") has historically been
a software technology and consulting company, specializing in providing
ergonomic solutions (human factors engineering) to individuals, major
corporations and government. On September 22, 1997, the Company acquired Drew
Shoe Corporation ("Drew Shoe"), a designer, marketer, manufacturer and
distributor of medical footwear. Drew Shoe had annual revenues of approximately
$15.1 million in 1997 and $14.6 million in 1996 and has been in business for
approximately 125 years. Drew Shoe provides the Company with ongoing revenue, as
well as potential new product opportunities through utilization of Company
technology (both existing and under development) into Drew Shoe products and a
platform for further possible acquisition of medical footwear and related
businesses.
The Company's revenues have historically been derived primarily from ergonomic
consulting services. In December 1997 the Board of Directors of the Company
decided to sell the operations of the ergonomic consulting services business due
to the inability of that business to generate operating profits for the Company.
In late February 1998, the Board of Directors of the Company decided to seek
alternative value for the operations of the HumanCAD Systems division as a
result of the unavailability of financing, on acceptable terms to the Company,
to further the necessary development activities of that division on a basis
which would enhance shareholder value. Since the acquisition of Drew Shoe, the
Company's revenues in the near term are expected to be derived principally from
the medical footwear business and related industries.
The Company's strategic focus is on building its presence in the medical
footwear and related industries and on broadening and strengthening the
development and commercialization of the Company's Intelligent Surface
Technology ("IST") and its proprietary "microvalve". Because of the significance
of Drew Shoe's operations to the ongoing operations of the Company, Drew Shoe is
considered a "predecessor" of the Company in the accompanying financial
statements.
On September 9, 1997, the Company announced that the 1998 Cadillac STS would
offer, as an option, a driver and passenger seat utilizing the Company's IST
technology through a license agreement with McCord Winn Textron, Inc., a
subsidiary of Textron, Inc.
The Company's principal subsidiaries consist of Drew Shoe Corporation (medical
footwear), BCAM Technologies, Inc. (principally IST and related technologies),
BCA Services, Inc. (principally human ergonomics consulting which has been
sold), HumanCAD Systems, Inc. (principally software development and marketing
which operations have been reduced substantially while the Company seeks a
strategic alternative for that business).
The Company is a now a medical footwear and technology company with a focus on:
(i) building its presence in medical footwear and related industries through
internal growth and planned acquisitions, (ii) accelerating the development and
commercialization of the Company's Intelligent Surface Technology ("IST") and
(iii) developing new technologies including its proprietary "microvalve." The
Company has collaborative research and development relationships with the State
University of New York at Stony Brook and with MCNC which provide valuable
resources in strengthening the Company's technologies.
The Company anticipates that its business plan will be enhanced, subject to the
availability of capital, by the acquisition of additional operating businesses
in the medical footwear and related businesses and by the further development,
subject to availability of capital, and commercialization of IST and
"microvalve". The Company hopes, over time, to incorporate its IST and
"microvalve" technology into intelligent medical footwear and other products.
Each of the Company's present and other businesses is described below.
(I) DREW SHOE CORPORATION
Drew Shoe is a designer, manufacturer, marketer and distributor of medical
footwear headquartered in Lancaster, Ohio. Drew has a 60,000 square foot
manufacturing and a 40,000 square foot distribution, executive office and
manufacturing facility in Lancaster, Ohio. Additionally, Drew operates
approximately 15 Retail medical footwear stores in various
<PAGE>
areas of the United States. Drew Shoe had annual revenues of approximately $15.1
million in 1997 and $14.6 million in 1996. Drew relies on its own retail stores
for distribution (approximately 25%), sales to approximately 2,000 specialty
retail stores, diabetic, prosthetic and pedorthic facilities and sales to the
Veterans Administration (approximately 11%). Revenues from the wholesale
division were approximately 75% in each of 1997 and 1996. Drew has been in
business for over 125 years and was primarily a comfort shoe manufacturer and
distributor until 1992, when it shifted its focus to medical footwear. Medical
footwear had been a small portion of the Company's business prior to 1992.
Approximately 60% or more of Drew Shoe's sales are of women's shoes. The Company
intends to continue to operate Drew Shoe as a manufacturer of medical footwear.
The Company believes that the industry in which Drew Shoe operates is highly
fragmented, has several relatively small competitors and represents an
opportunity for consolidation within the industry. Further, the Company believes
that related industries such as custom orthotics and other comfort products may
be a good synergistic fit for the Company and that such companies may also
represent an opportunity for consolidation. In addition to the opportunities
which may exist in the consolidation of medical footwear, orthotic and related
industries, the Company believes that it brings important "comfort" technology
which may have application in medical footwear and related products. As such,
Drew Shoe provides the Company with ongoing revenue, as well as potential
opportunities through (i) a platform for possible further acquisitions of
medical footwear and related businesses (ii) profit and systems improvement
opportunities and (iii) the possible utilization of Company technology (both
existing and under development) in medical footwear, orthotic and other
products.
Since the acquisition of Drew Shoe, the Company's revenues in the near term are
expected to be largely affected by the medical footwear business however, the
operations of Drew Shoe alone are not sufficient to turn the Company profitable
in the immediate future.
The Company has financed the acquisition of Drew Shoe with convertible notes
that will add significant cash and non-cash charges for interest and financing.
(See Recent sales of unregistered securities and Note 6 to Consolidated
Financial Statements for a discussion of the acquisition financing as well as
the April 1998 restructure which secures the financing with Company assets and
accelerates the maturity date of the obligation to April 1999.)
(II) INTELLIGENT SURFACE TECHNOLOGY ("IST")
Since 1991, the Company has developed technologies which resulted in eight
issued patents, as well as various notice of allowance and additional patent
filings related to its IST. IST empowers surfaces to automatically measure any
part of the body touching that surface and then, in real time, adjust that
surface to conform to that user's body to provide the ultimate in comfort and
fit. Such a surface is considered an intelligent surface because it is able to
learn about the user and recognize patterns of the user's activities through its
proprietary software. The Company has identified applications for this
technology in the primary areas of seating, footwear and bedding. In addition,
the technology can be used for handtools, exercise equipment, helmets, etc. The
Company's strategy has been to license such technology to companies that can
develop products that can exploit this technology.
Current Licensees
Textron. The Company and McCord Winn Textron Inc., a subsidiary of Textron
Inc. ("Textron") signed a Development and License Agreement in March 1993,
amended in October 1993 and August 1996, whereby the Company granted an
exclusive worldwide license to Textron to use the IST patents and know-how in
the manufacture, use and sale of seats, and seating components for the
transportation industry, wheelchairs, office furniture applications and hospital
beds.
In September 1997, Textron began selling an automobile seat to the Cadillac
Division of General Motors for inclusion, as optional equipment, in the driver
and front passenger seat for the 1998 Cadillac Seville STS model. Textron is
obligated to pay the Company a royalty, after deduction of an agreed upon credit
($150,000) over four or more years, for the use of the Company's technology in
the sale of the systems. There were no revenues in the 1997 financial
statements from the sales of Textron. The Company anticipates, based upon the
information on sales activity and other information provided by Textron, that it
will record license revenues in the second half of 1998.
The August 1996 amendment obligated Textron to pay royalties to the Company
through December 31, 1999, for any products designed using the Company's IST.
After January 1, 2000, Textron shall be obligated to pay the Company royalties
only for any products designed which actually incorporate IST patents and
know-how transmitted to Textron by the Company after May 31, 1996. The Company
has disclosed to Textron that it has received four patents and one "Notice of
Allowance" after May 31, 1996.
Reebok. In January 1994, the Company and Reebok International Ltd. ("Reebok")
signed a world-wide exclusive licensing and development agreement for the use of
IST for certain footwear. In addition, Reebok has a right of first refusal to
obtain
3
<PAGE>
exclusive licenses to use IST on athletic, sport and fitness equipment fields of
use. The fields of medical equipment and orthopedic devices are specifically
excluded from the Reebok license.
No revenue has been realized from this license. The Company and Reebok are
continuing discussions.
Sealy. In August 1996, the Company signed an agreement with Sealy, Inc. in which
Sealy, Inc. has the option to license IST for its adjustable bed and a right of
first refusal as applied to all bedding products (excluding medical bedding
applications). No revenue has been received in 1997 from this license.
The Company is in various stages of discussions with other companies about the
possible license of IST for use in consumer seating and other products.
(III) PROPRIETARY SOFTWARE DEVELOPMENT
Since 1989, the Company has developed, marketed, maintained, and continuously
upgraded its Mannequin Pro(TM) software product. This proprietary software
product was further developed and marketed by the Company's HumanCAD(R) division
during 1997. In December 1997, the Company received a commitment for certain
financing of the planned development and marketing activities of HumanCAD in
1998. The Company took an additional facility in Waterloo, Canada and hired
additional sales and marketing and development personnel subsequent to that
time. In late February 1998, the Company was advised by the funding source that
it would no longer be interested in going forward with the planned financing.
The Company then determined to seek alternative value for its investment in
these software products and significantly reduced its development and marketing
efforts. The operations of the Human CAD division are considered a discontinued
operation in the accompanying financial statements with a measurement date of
February 1998. As such, additional charges to operations will be made in 1998.
The related products of the Human CAD division are as follows:
Mannequin Pro(TM)
MannequinPro(TM) is a human modeling program that enables the user to render
3-dimensional scalable humod figures on a personal computer (PC). These figures
can be articulated into any position and then can be viewed from any angle,
distance or perspective. The result of that view can be printed, plotted or
exported to other graphics software for further enhancement of the image. The
figures can walk, bend, reach and grasp objects. A user can test the
functionality of the design of almost anything used by humans. The Company has
recently upgraded a Windows(R) version that processes in all Windows(R)
platforms. The software is compatible with CAD and other graphic programs, and
has motion capture capabilities useful for graphical illustrations and motion
analysis. The Company believes that several universities, design organizations
and government agencies, including NASA, are current users of the earlier
version of MannequinPro(TM). Human CAD has also developed a low cost version of
MannequinPro called Mannequin OnSite.
(IV) ERGONOMIC CONSULTING SERVICES
Until February 9, 1998, the Company had provided ergonomic consulting services
in two areas: (i) Traditional Ergonomic Consulting Services, in Ergonomic
Product Assessment and Redesign, and Ergonomic Workplace Assessment and (ii)
Software Based Consulting Services, tailored to the implementation and use of
the HumanCAD(R) line of ergonomic software products. Prior to the acquisition of
Drew Shoe, Ergonomic Consulting Services represented the majority of revenues
(over 75%) in 1997 and 1996. On February 9, 1998, this business was sold to a
third party in exchange for 7.5% of revenues under contracts in process assumed
by the third party plus certain defined future revenues.
In Ergonomic Product Assessment and Redesign services, the Company performed
comprehensive subjective and objective ergonomic testing on products that
quantifies the product's relationship in terms of comfort, fit, useability and
user performance to humans. This knowledge was used by product developers,
manufacturers and industrial design firms to improve existing products and/or to
develop new ones.
4
<PAGE>
In Ergonomic Workplace Assessment services, the Company provided industrial
companies, government, and insurance companies with advice on how to reduce
musculoskeletal injuries, through its proprietary EARLY(R) (Ergonomic Assessment
of Risk and Liability) services and other consulting services. Other benefits
are the potential for improved productivity, enhanced product and service
quality.
SALES AND MARKETING
Drew Shoe
Wholesale
Drew Shoe markets its products through eleven independent sales representatives
and through the efforts of four employees who are part of a customer service
telemarketing team. The sales representatives call on retail customers
periodically during the year and solicit new orders based upon new product
samples and seasonal catalogues, which reflect the Company's complete product
line. The customer service telemarketing team calls or receives calls from
customers who want to place fill-in orders. The Company's products are
advertised locally by Drew customers. Drew participates in these costs based
upon a preset formula. All orders are subject to credit approval and are shipped
from Lancaster, Ohio.
Retail
Drew Shoe retail stores service the medical footware needs of the communities in
which they are located. Each store communicates its marketing message via
newspaper advertising, direct mail and by calling on appropriate doctors in the
community. Each store has a qualified staff in-house to assist the customer in
meeting their specific footware needs.
Marketing Strategy for Licensing IST
In order for the Company to obtain new licensees, the Company's marketing
strategy has focused on identifying organizations that:
-- Are large,
-- Are financially strong,
-- Have marketing presence, and
-- Have the financial resources to commercialize the technology
The Company will license the IST technology to organizations that meet the above
criteria and will assist those organizations in commercializing the technology.
Research and Development
The Company's research and development is focused on enhancing and
commercializing the Company's core technologies. The Company attempts to
minimize spending on research. Therefore, the Company typically will try to
acquire the rights to use an existing technology, if available, rather than
spend money and effort to invent a new technology. The Company will, however,
fund research for technology, when the needed technology is not available. For
example, in the case of certain components (i.e., a self-generating power supply
and an intelligent switch) which are necessary to employ IST for handtools and
footwear applications, the Company is seeking to acquire the rights to
technology to manufacture such components instead of trying to invent those
technologies. However, in the case of other control components (i.e., the
microvalve that will control the "air pressure"), the Company is devoting
resources to develop that technology, in order to be in a better position to
exploit the commercial opportunities of IST in a miniaturized environment. The
Company has a collaborative arrangement with MCNC to develop a microelectric
mechanical device "microvalve" using MEMS (micro electric mechanical systems)
technology. In the area of development, the Company is focusing on software and
application engineering for IST to support products of its licensees. Further
software developments include principally IST.
5
<PAGE>
The Company uses its internal resources and subcontractors, as needed, in its
research and development activities. For example, the Company has established a
collaborative research and development relationships with the State University
of New York at Stony Brook, MCNC and the New Jersey Institute of Technology, and
plans to establish additional relationships with other universities, and
government laboratories, as necessary.
Competition
Drew Shoe
The Company competes in a highly fragmented medical and comfort niche market
segment of the footware market. Competition includes P.W. Minor, whose products
are very similar to those offered by Drew Shoe. Various other companies compete
with Drew on the fringe of the medical footware market, including SAS, a large
manufacturer and retailer of comfort oriented footware for women and men.
Management of the Company believes that its unique IST technology and know-how
may give it a competitive advantage. Although there may be similar systems to
the Company's IST, the Company believes that its patents and know-how protect
its technology from competition.
Suppliers
The Company's traditional business involved providing services, and the
materials it used in its business may be obtained from numerous suppliers. Drew
Shoe depends on various raw materials and components to manufacture its shoes,
many of which are dependent on one supplier. Drew Shoe does not have binding
long-term supply contracts with these suppliers. Approximately 15% of Drew
Shoe's supplies, primarily leather, are provided by Italian companies. The
Company believes that its relationships with its vendors are satisfactory.
Government Regulation
The Company's present and proposed activities are not generally subject to
government regulation in the United States or other countries. The costs and
effects of complying with environmental laws by the Company are not material.
Proprietary Information
The patent process is a significant protection for the Company's intellectual
property. The Company has obtained eight patents and has filed nine additional
United States patent applications relating to its IST. One of the patents filed
is also very significant since it is for a critical component needed to
miniaturize the application of the IST. Such miniaturization will allow the
Company to a) accelerate the commercialization of many applications, b) enter
the very large and expanding medical footwear market with applications for
diabetics, arthritics and the aging population, and c) provide applications to
other industries, such as the hand tool industry. The Company also has five U.S.
patents in fields other than IST.
Major Customers
Drew Shoe
During 1996 and 1997 the Veteran's Administration was Drew's largest customer
accounting for approximately 11% of revenue each year. No other customer
accounted for more than 5% of Drew's revenues in either year.
IST - The major customer for IST as the Company enters 1998 is Textron. See
above.
6
<PAGE>
The "Year 2000" issue
At Drew Shoe, there are information systems used for general accounting,
wholesale operations, retail operations and factory management. In October 1997,
Drew Shoe, with the assistance of consultants, began a comprehensive review of
its information systems, most of which are in need of upgrade in order to keep
pace with the growth strategies of the Company. In December 1997, Drew Shoe
hired a full time Director of Information Systems to lead the Company's efforts
in this area. In connection with such efforts, Drew Shoe made capital
expenditure commitments of approximately $50,000 to upgrade certain hardware and
expects to make certain additional commitments for hardware, peripheral
equipment, software and software upgrades in connection with its comprehensive
review of its information systems. These efforts are expected to result in
substantial change to the information systems of Drew Shoe over the coming
eighteen months. In each effort, the "Year 2000" problem is being addressed as a
priority item. Management expects to complete the changes necessary to be "Year
2000 Compliant" prior to the year 2000. Since the scope of proposed changes to
the information systems at Drew Shoe is still under review, management is not
able to estimate the cost, at this time, of changes to the systems. However,
management does not believe that the cost to be "Year 2000 Compliant" is a
material additional cost to the changes which it would plan to make to its
systems to accommodate planned growth strategies.
At the Company's corporate office, information systems are principally utilized
for general accounting. Such system is not "Year 2000" compliant and the Company
expects to upgrade such system during 1998 in order to be compliant. The Company
does not believe that the cost of compliance with "Year 2000" will be material
at its headquarters.
Employees
As of December 31, 1997, the Company had approximately 275 employees, including
approximately 255 persons employed by Drew Shoe, 5 employees devoted to
Ergonomic Consulting and technology, 8 employees devoted to HumanCAD, 4
corporate administrative employees and 3 executive officers. Approximately 10 of
those employed at December 31, 1997 have been terminated or notified of
termination in connection with the sale of the Ergonomic Consulting Division and
the substantial reduction in activity of the HumanCAD division. Of the 255
employees at Drew Shoe, approximately 18 are employed part time and
approximately 155 are covered by a collective bargaining agreement that expires
in May 1998. In addition, the Company has established a collaborative research
and development relationship with the State University of New York at Stony
Brook, with plans to establish additional relationships with other universities,
government laboratories, and other sub-contractors.
The Company has been able to attract and retain skilled employees by offering
competitive salaries and benefits. The Company believes that its relationship
with its employees is good.
Forward-Looking Statements
Information set forth in this Form 10-KSB regarding the Company's plans for
future operations constitutes "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Any forward-looking statements
should be considered in light of the factors set forth in the "Factors That May
Affect Future Results" section of this Form 10-KSB.
ITEM 2. DESCRIPTION OF PROPERTY
Since 1990, the Company has leased office space at 1800 Walt Whitman Road,
Melville, New York. The Company's lease expires on March 31, 2000. The current
annualized lease rate for this space is approximately $150,000, which is subject
to annual increases. The facility, which contains approximately 8,400 square
feet, includes biomechanics research laboratories and an ergonomic library as
well as offices. The laboratories were used both for testing and for the
redesign of products and are largely unused as a result of the discontinuance of
the Ergonomic Consulting Services Division. The Company is in discussions with
its landlord and a prospective sub tenant about subletting this facility in the
first half of 1998 and moving into smaller quarters. The Company's HumanCAD
division has two development facilities, one in Toronto, Canada and one in
Waterloo, Canada. Such facilities contain an aggregate of approximately 3,000
square feet
7
<PAGE>
and were utilized for development and executive offices. The Company expects to
sublet such facilities, if possible. Drew Shoe owns a 40,000 square foot
facility at 252 Quarry Road, Lancaster, Ohio. This facility serves as Drew
Shoe's executive office as well as warehouse and certain manufacturing
facilities. Drew Shoe also owns a 60,000 square foot manufacturing facility on
Forest Rose Avenue in Lancaster, Ohio that houses its principal manufacturing
operations. Drew Shoe leases retail space to house its 15 retail outlets. Such
facilities call for aggregate annual rentals of approximately $286,000 per year.
ITEM 3. LEGAL PROCEEDINGS
In January 1998, Ulin & Holland Incorporated ("U & H") filed suit against the
Company's Drew Shoe subsidiary in United States District Court for the District
of Massachusetts. The suit alleges that U & H was retained in 1992 by Drew Shoe
pursuant to which U & H alleges that it is due a fee of not less than $297,000
in connection with the Company's acquisition of Drew Shoe. Drew Shoe disputes
this claim and the Company intends to vigorously defend this action.
There are no other material legal proceedings pending against the Company.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
At its 1997 Annual meeting of shareholders held on February 19, 1998, the
following matters were brought for a vote of the shareholders:
Votes
Proposal Votes for against Abstain
-------- --------- ------- -------
- ------------------------------------------------------------------------------
1. Adoption of a staggered Board of Directors 10,076,491 386,336 56,560
2. Election of Directors
- Michael Strauss 16,743,045 282,455
- Robert B. Wong 16,738,045 287,455
- Norman B. Wright 16,680,460 345,040
- Charles G. Schuyler 16,722,560 302,940
- Joel L. Gold 16,696,345 329,155
- Glenn F. Santmire 16,746,455 279,055
- Mark L. Plaumann 16,745,745 279,755
- Stephen Savitsky 16,744,945 280,555
3. Approval of an increase in the number of
shares available for grant under the 1995
stock option plan 16,162,581 736,869 126,050
4. Approval of a change to the Corporation's
ByLaws to permit the issuance of up to
2,000,000 shares of Preferred Stock 9,916,047 1,338,736 208,045
5. Approval of a change to the
Corporation's ByLaws to increase the
Authorized Common Shares from
40,000,000 to 65,000,000 8,003,173 1,173,326 330,200
6. Ratification of the appointment
of Ernst & Young L.L.P. as the
Corporation's auditors for 1997 16,827,030 28,740 169,730
PART II
ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.
The Common Stock of the Company is quoted primarily on the NASDAQ Small Cap
Market under the symbol BCAM. It is also traded on the Boston Stock Exchange
under the symbol BAM.
8
<PAGE>
The following table sets forth the high and low closing bid quotations for the
Common Stock as reported by NASDAQ and the Boston Stock Exchange for each
calendar quarter during 1997 and 1996. The NASDAQ Small Cap market quotations
reflect inter-dealer prices without retail markup, markdown or commission and do
not necessarily represent actual transactions.
NASDAQ
------
1997 High Bid Low Bid
---- -------- -------
First Quarter 1 3/8 27/32
Second Quarter 1 1/8 11/16
Third Quarter 1 7/8 23/32
Fourth Quarter 1 31/32 1
1996 High Bid Low Bid
---- -------- -------
First Quarter 1 1/4 29/32
Second Quarter 1 5/16 29/32
Third Quarter 1 23/32 15/16
Fourth Quarter 1 7/16 13/16
Boston Stock Exchange
---------------------
High Low
---- ---
1997 Sales Price Sales Price
---- ----------- -----------
First Quarter 1 1/4 27/32
Second Quarter 1 3/32 3/4
Third Quarter 1 3/32 23/32
Fourth Quarter 1 5/8 1 5/8
High Low
---- ---
1996 Sales Price Sales Price
---- ----------- -----------
First Quarter No Activity No Activity
Second Quarter 1 1/4 1 1/16
Third Quarter 1 19/32 1
Fourth Quarter 1 7/16 7/8
Holders
There were approximately 327 record holders of the Company's Common Stock as of
April 10, 1998.
Dividends
The Company has paid no cash dividends on its Common Stock since its inception
and does not anticipate paying cash dividends on its Common Stock in the
foreseeable future.
Recent Sales of Unregistered Securities
(i) Sale of common stock and warrants ($1,075,000) - Between January 15
and March 28, 1997, in consideration for $1,075,000, the Company sold to
accredited investors an aggregate of 1,075,000 shares of Common
9
<PAGE>
Stock at $1.00 per share, and 1,075,000 Non-Redeemable Class AA Warrants to
purchase an additional 1,075,000 shares of Common Stock at an exercise price of
$.65 per share exercisable through March 31, 2002.
The purchasers of the securities are set forth in the following
table:
Common shares Common shares
Name of purchaser Amount paid issuable under warrants
- ----------------- ----------- -------- --------------
621 Partners $ 260,000 260,000 260,000
Appleton Associates 120,000 120,000 120,000
R. Weil & Associates 320,000 320,000 320,000
Karen Weil 100,000 100,000 100,000
David Latter 25,000 25,000 25,000
Howard Weingrow 50,000 50,000 50,000
Peter Orr 50,000 50,000 50,000
Joseph Offenberger 25,000 25,000 25,000
David Schultz 25,000 25,000 25,000
Howard Seiberman 50,000 50,000 50,000
Joe Schueller 50,000 50,000 50,000
---------- --------- ---------
$1,075,000 1,075,000 1,075,000
---------- --------- ---------
Kirr Marbach & Company, LLC ("Kirr Marbach") is a general partner of 621
Partners, Appleton Associates and R. Weil & Associates which in the aggregate
are entitled to receive, or to direct the receipt of, dividends from, and the
proceeds from sale of, all of the shares beneficially owned by Kirr Marbach.
The Registrant claims exemption from registration of this placement by virtue of
Section 4(2) of the Securities Act of 1933.
(ii) Convertible Preferred stock of BCA Services, Inc. ("BCA"), a
subsidiary of the Registrant ($1,200,000) - On July 22, 1997 BCA Services, Inc.
("BCA"), previously a wholly-owned subsidiary of the "Company", commenced an
Offering (the "Offering") to sell up to 150 shares of BCA's Convertible
Preferred Stock (the "Preferred Stock") for a total consideration of $1.5
million in a private offering to accredited investors.
The Preferred Stock was convertible into shares of the Company's Common Stock
("Common Stock") at a price equal to 70% of the average closing bid price of the
Common Stock over a three day trading period ending on the day preceding the
conversion date (the "Variable Conversion Price"). The Conversion Price could
not be greater than 100% of the Variable Conversion Price on the first closing
date (the "Fixed Conversion Price"). The Fixed Conversion price was $0.6563. In
July and September 1997, the Company sold 100 shares ($1,000,000) of Convertible
Preferred stock to Austost Anstalt Schaan ($500,000) and UFH Endowment LTD.
($500,000). Between November 1997 and March 1998, all of the Convertible
Preferred stock issued was converted into common stock of the Company.
In addition, purchasers of the Convertible Preferred stock received
Non-Redeemable Class BB Warrants to purchase 50,000 shares of Common Stock,
exercisable at $0.7219. The warrants have a term of five years and the Common
Stock underlying the warrants contains registration rights.
On September 18, 1997, BCA closed a separate offering of its Preferred Stock
plus warrants for $200,000 on similar terms and conditions as the Offering
(excluding the existing fixed conversion feature and certain fees). As a result
of this offering, 20 shares of Preferred Stock (convertible into the Company's
common stock at a maximum price of $0.9331 per share) were issued, along with
Non-Redeemable Class CC Warrants to purchase up to 10,000 shares of Common Stock
(at $1.0264 per share). The purchasers of the securities were Arcadia Mutual
Fund, which purchased 15 shares of Preferred Stock and warrants to purchase
7,500 shares of the Company's common stock, and David Morgenstern, who purchased
5 shares of Preferred Stock and warrants to purchase 2,500 shares of the
Company's common stock. All of the Convertible Preferred stock issued in this
offering was converted to common stock of the Company at an average price of
approximately $0.79 per share prior to December 31, 1997. . The Registrant
claims exemption from registration of this placement by virtue of Section 4(2)
of the Securities Act of 1933.
The two private placements of BCA preferred stock were made with the assistance
of a placement agent, Corporate
10
<PAGE>
Capital Management, who charged a commission of 8% in fees and 2% in expenses
plus warrants to purchase up to 50,000 shares of common stock of the Registrant
at approximately $0.66 per share, for five years for the first offering and 6%
in fees and no warrants for the second offering.
In response to positions recently taken by the Securities and Exchange
Commission, Emerging Issues Task Force Statement D-60 has been issued which
requires accounting for securities issued which are convertible into common
stock at a value which is "beneficial" at the date of issuance (such as the
preferred stock described above and the 10%/13% Convertible Notes and Warrants
described below). This accounting results in significant charges to operations
in connection with these financings as further described in Notes 6 and 7 to
the Consolidated Financial Statements.
(iii) 10%/13% Convertible Notes and Warrants ($6,000,000) - In order to
fund the acquisition of Drew Shoe and provide working capital to the Company, On
September 19, 1997, the Company issued subordinated convertible notes to eight
investors in the aggregate amount of $6,000,000 (the "Convertible Notes"). The
Convertible Notes are due as amended in April 1998 (see "Debt restructuring"
below) on April 16, 1999, unless at any time after September 19, 1998, they are
converted, at $.80 per share, into 7,500,000 shares of Common Stock of the
Company. The conversion feature is subject to antidilution in certain
circumstances including the issuance of Common Stock and warrants in 1998
discussed below. The Convertible Notes bear an interest rate of 10%, payable
semi-annually, but the Company, at its discretion, may pay interest in the form
of its convertible notes in which case the annual interest rate becomes 13% with
semi-annual compounding. The Convertible Notes require the Company to maintain
compliance with certain financial covenants including maintenance of minimum
levels of interest coverage and net worth (as defined).
In addition, the Company issued to the noteholders Non-Redeemable Class DD
Warrants to purchase as amended in April 1998, 2,400,000 shares of common stock,
exercisable at $1.75 per share at any time prior to September 19, 2002.
The market value of the Company's common stock on the Nasdaq SmallCap market on
the date of the transaction was approximately $1.50.
The purchasers of the securities are set forth in the following table:
Common shares Common shares
Name of purchaser Amount paid issuable under warrants
- ----------------- ----------- -------- --------------
Impleo, LLC $5,000,000 6,250,000 2,000,000
621 Partners 150,000 187,500 60,000
R. Weil & Associates 155,000 193,750 62,000
David M. Kirr 165,000 206,250 66,000
Terry B. Marbach 165,000 206,250 66,000
Gregg T. Summerville 165,000 206,250 66,000
Ralph Weil 100,000 125,000 40,000
Joseph Schueller 100,000 125,000 40,000
---------- --------- ---------
$6,000,000 7,500,000 2,400,000
========== ========= =========
Kirr Marbach & Company, LLC, a registered investment advisor, is the managing
general partner of 621 Partners, Appleton Associates and R. Weil & Associates,
and together with Messrs Kirr, Marbach and Summerville may be deemed to
constitute a group within the meaning of Regulation 13D-G.
The private placement of convertible notes and warrants to Impleo, LLC was made
with the assistance of an investment banker, Josephberg Grosz and Company, who
charged a cash fee of 6% ($300,000) of proceeds plus 187,500 shares of common
stock, and warrants to purchase 500,000 shares of common stock, at $0.80 per
share, of the Registrant. The remaining $1,000,000 of proceeds was not subject
to a commission.
The Registrant claims exemption from registration of this placement by virtue of
Section 4(2) of the Securities Act of 1933.
In response to positions recently taken by the Securities and Exchange
Commission, Emerging Issues Task Force Statement D-60 has been issued which
requires accounting for securities issued which are convertible into common
stock at a value which is "beneficial" at the date of issuance (such as the
preferred stock and the 10%/13% Convertible Notes and
11
<PAGE>
Warrants described above). This accounting results in significant charges to
operations in connection with these financings as further described in Notes 6
and 7 to Consolidated Financial Statements. The Company also has, under
generally accepted accounting principles, recorded approximately $1,872,000 as
the estimated value of the detachable warrants issued in connection with the
convertible notes. Reference is made to Note 6 of the Consolidated Financial
Statements of the Company.
Debt Restructuring - Effective April 14, 1998 the Company and the holders of the
10%/13% Convertible Notes and related warrants entered into a First Amendment
(and related Stock Pledge Agreement and Security Agreement) of the September
1997 Note Purchase Agreement in order to restructure the obligation. The key
elements of the restructuring are as follows: (1) waiving of the Company's
violations of the financial covenants at December 31, 1997 (as well as certain
other breaches of the agreement), (2) eliminating the financial covenants
through April 16, 1999, (3) securing the obligation with a pledge of all of the
assets of the Company (excluding the assets of Drew Shoe which are already
pledged to a bank), including the stock of the Company's subsidiaries, (4)
accelerating the maturity date for the obligation from September 19, 2002 to
April 16, 1999, (5) cancellation of Class DD warrants to purchase 400,000 shares
of common stock of the Company, (6) issuance to the holders a total of 10% of
the common shares of the Company's subsidiaries Drew Shoe Corporation and BCAM
Technologies, Inc. The Company expects to take a significant charge to
operations in 1998 in connection with the finalization of the restructuring of
the debt.
(iv) Sale of Common Stock and Warrants (April 1998)
Beginning on April 14, 1998, the Company commenced a private offering of its
common stock and warrants. The offering contemplates aggregate proceeds of
$2,000,000 for the purchase of 1,980,198 shares of common stock of the Company
and warrants to purchase 250,000 shares of common stock at $2.05 for three years
by seven accredited investors. On April 15, 1998 the Company issued 1,881,188
shares of common stock, together with warrants to purchase 237,500 common shares
at $2.05 per share for three years, to private investors in exchange for
$1,900,000, less $475,000 held in escrow pending the Company's filing of a
registration statement covering the shares and shares underlying the warrants
prior to June 13, 1998. The Company has agreed to register such shares and has
agreed to penalties of 3% per month should the registration statement not be
declared effective within 130 days.
The number of shares issuable to these investors will be "repriced" pursuant to
a schedule initially in four $300,000 increments and then in four $200,000
increments on eight occasions commencing with the effectiveness of a
registration statement covering the shares and again 60 days later and then in
30 day intervals. On such dates, the investor would receive the additional
number of shares, if any, that result from the difference between the number of
shares actually issued and the number of shares which would have been issued
using a 23% discount to the market price, as defined, at that time. The
operation of this provision could result in significantly greater number of
shares being issued. The investors have agreed not to sell any shares before at
least 120 days after the closing. The Company is exposed to significant
penalties for failure to have a registration statement declared effective
covering such shares within 130 days, has agreed not to issue certain financings
and has agreed to pay a placement agent a 6.5% fee in connection with the
transaction.
ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS
Except for the historical information contained herein, the following discussion
contains forward looking statements that involve risk and uncertainties. The
Company's actual results could differ materially from those discussed herein.
Factors that could cause or contribute to such differences include, but are not
limited to, those discussed below in Factors That May Affect Future Results
Overview
The Company has historically been a software technology and consulting company,
specializing in providing ergonomic solutions (human factors engineering) to
individuals, major corporations and government. On September 22, 1997, the
Company acquired Drew Shoe Corporation ("Drew Shoe"), a designer, marketer,
manufacturer and distributor of medical footwear. Drew Shoe had annual revenues
of approximately $15.1 million in 1997 and $14.6 million in 1996 and has been in
business for approximately 125 years. Drew Shoe provides the Company with
ongoing revenue, as well as potential new product opportunities through
utilization of Company technology (both existing and under development) into
Drew Shoe products and a platform for further possible acquisition of medical
footwear and related business.
The Company's revenues have historically been derived primarily from ergonomic
consulting services. In December 1997 the Board of Directors of the Company
decided to sell the operations of the ergonomic consulting services business as
discussed in Note 8 to Consolidated Financial Statements. In late February 1998,
the Board of Directors of the Company decided to seek alternative value for the
operations of the HumanCAD software division as discussed in Note 8 to
Consolidated Financial Statements.
Since the acquisition of Drew Shoe, the Company's revenues in the near term are
expected to be derived principally from the medical footwear business. The
Company is now a medical footwear and technology company with a focus on: (i)
building its presence in medical footwear and related industries through
internal growth and planned acquisitions, (ii) advancing the development and
commercialization of the Company's Intelligent Surface Technology ("IST") and
(iii) developing new technologies including its proprietary "microvalve." The
Company has collaborative research and development relationships with the State
University of New York at Stony Brook and with MCNC which provide valuable
resources in strengthening the Company's technologies. Because of the
significance of Drew Shoe's operations to the ongoing operations of the Company,
Drew Shoe is considered a "predecessor" of the Company in the accompanying
financial statements.
See Liquidity and Capital Resources and Note 6 to Consolidated Financial
Statements regarding the restructure of certain long-term debt.
Results of Operations
Results of operations for 1997 are significantly impacted by restructuring
developments including: (1) the acquisition of Drew Shoe (2) the discontinuation
of the Ergonomic Consulting Services and HumanCAD software divisions and (3)
charges and costs related to the financing to acquire Drew Shoe and other
financing during the year.
12
<PAGE>
Drew Shoe acquisition - Effective September 22, 1997, the Company acquired all
of the outstanding Common Stock of Drew Shoe for approximately $4.7 million plus
the assumption of liabilities. Drew Shoe is a designer, manufacturer, marketer
and distributor (both wholesale and retail) of medical footwear. The Company has
accounted for its acquisition of Drew Shoe under the purchase method of
accounting. As such, the results of operations of Drew Shoe are consolidated
with the Company's 1997 operations for approximately three months and eight days
beginning on September 22, 1997. Drew Shoe had operating income (before
subsidiary interest and finance costs, net of interest income, of approximately
$106,000) of approximately $112,000. Further, the Company expects to take steps
to build the revenue base and profitability of Drew Shoe. The Company expects
that its revenues in the near term will be principally from Drew Shoe. Drew Shoe
had revenues of over $14.6 million in calendar 1996
Discontinued operations - As discussed in greater detail in Note 8 to the
Consolidated Financial Statements, the Company has recorded the operations of
the Ergonomic Consulting Services Division ("ECSD") and HumanCAD Systems
Division ("HCAD") as discontinued operations. The two divisions represented
combined revenues and operating losses of approximately $602,000 and $1,356,000,
respectively, in 1997. These divisions were discontinued because ECSD did not
generate operating profits for the Company and HCAD required capital which the
Company could not obtain on favorable terms. Because the measurement date for
the HumanCAD discontinuance is in late February 1998, there will be additional
losses recorded from this activity until its discontinuance in the first quarter
of 1998.
Charges and costs related to financings (including minority interest charge) -
Interest and financing costs for the year ended December 31, 1997 consisted
principally of: (i) non-cash amortization of Unamortized charge for beneficial
debt conversion of approximately $1,635,000 as a result of the application of
EITF Statement D-60, (ii) costs of financings which the Company chose not to
complete of approximately $130,000, (iii) amortization of debt discount of
approximately $95,000, (iv) amortization of Deferred finance costs of
approximately $75,000 and (v) accrual for interest and all other of
approximately $313,000. See Note 6 to financial statements regarding the
significant non-cash charge which results from the accounting under EITF
Statement D-60.
In addition to the interest and financing costs discussed above, the Company
recorded a non-cash charge of approximately $788,000 to minority interests
during 1997. This charge reflects the accounting for the beneficial conversion
feature of subsidiary preferred stock issued during 1997. Such accounting, in
accordance with EITF Statement D-60 is described in Note 3 and 7 to the
consolidated financial statements.
Ongoing selling, general and administrative costs - Ongoing selling, general and
administrative costs before considering such costs at the acquired company (Drew
Shoe) totaled approximately $1,501,000 in 1997 compared to approximately
$1,408,000 in 1996. The increase consists principally of approximately $150,000
related to increases in executive compensation and bonuses over the prior year,
offset by various decreases.
Research and development costs - In 1997, research and development costs consist
principally of costs associated with the Company's development of a "microvalve"
in collaboration with a third party, MCNC.
License revenues - License revenues consist principally of revenues received
from IST products and have not been significant to date. One Company's licensee,
Textron, has launched a new product, in September 1997, utilizing IST in an
automobile seat. It is expected that such product would generate license
revenues for the Company in approximately the fourth quarter of 1998.
Liquidity and Capital Resources
The September 22, 1997 purchase of Drew Shoe results in a significant
change to the financial position, working capital, capital resources and
liquidity of the Company. This results from: (i) the issuance of $6,000,000 of
10%/13% Convertible Notes, due 1999, and Warrants, (ii) the secured credit
facility with a bank and (iii) the purchase of significant operating assets in
Drew Shoe (principally inventory, receivables, facilities and equipment), net of
expenses and liabilities associated with the transactions. The Company's
financial position, working capital and liquidity was also affected by the July
and September issuance of an aggregate of $1,200,000 of convertible preferred
stock of a subsidiary, all of which has been converted into common stock of the
Company at March 31, 1998 (see Note 7 to consolidated financial statements) and
the January through March 1997 private placement of common stock and warrants
for an aggregate consideration of $1,075,000. The changes in Company's financial
position include the following:
13
<PAGE>
December 31, 1997 December 31, 1996
----------------- -----------------
Cash $ 1,594,000 $ 526,000
Working capital $ 6,716,000 $ 438,000
Long-term debt (see below) $ 7,972,000 $ 0
Total Assets $14,177,000 $1,304,000
Shareholders equity $ 2,094,000 $1,015,000
See Notes 5, 6 and 7 to Consolidated Financial Statements for a description of
the acquisition and the terms of the 10%/13% Convertible Notes, secured credit
facility, convertible preferred stock and short term note payable. The structure
of the secured credit facility with a bank is such that Drew Shoe cannot
transfer cash to the Company other than in the ordinary course of business.
Subsequent to December 31, 1997 a planned financing directed toward the
development and marketing efforts of the HumanCAD division was terminated by the
potential funding source. The losses of that division in the first quarter of
1998 are expected to be material to operations and the Company's liquidity.
The Company requires additional capital in order to fund its operations during
1998. During April 1998, the Company commenced a private placement to raise an
aggregate $2,000,000 through the issuance of common stock and warrants (See --
Recent issuance of unregistered securities). The Company received approximately
$1,425,000 of gross proceeds from this planned financing by April 16, 1998. This
financing would permit the Company to continue to pursue its business strategy
for approximately 12 months. Thereafter, the Company may require additional
capital to pursue its business plan (also see next paragraph). Further, the
capital raised in this financing would most likely not be sufficient to fund any
significant acquisitions and is not planned to be used for that purpose. The
Company expects that it will be required to raise additional capital in order to
fund its acquisition strategy and to develop and exploit its "microvalve". On
April 14, 1998, the Company and the holders of the 10%/13% Convertible Notes
agreed to restructure the 10%/13% Convertible Notes (See -- Recent sales of
unregistered securities and Note 6 to financial statements). As part of the
restructuring, the Company agreed to accelerate repayment of the obligation
from September 19, 2002 to April 16, 1999 and to secure the obligation with all
of the assets of the Company. As a result, the Company has a significant capital
requirement to repay this obligation ($6,000,000) in approximately one year or
face default and possible foreclosure on the security. It is the Company's
intention to refinance or otherwise restructure this obligation.
Factors That May Affect Future Results
The Company's future operating results are dependent on the Company's ability
to: (i) obtain sufficient capital to fund its development, growth and
acquisition plans, (ii) generate profitable growth at Drew Shoe, (iii) generate
sufficient profits from operations to fund its debt service, (iv) identify and
successfully close potential acquisitions on terms that are favorable to the
Company (vi) achieve further successful development of IST and increase the
number of licensees, and the commercialization of IST by its licensees, (vii)
introduce IST in medical footwear and orthotic products and (viii) successfully
develop the "microvalve", and in addition they are also dependent on, (ix)
general economic conditions and conditions in the financial and medical footwear
markets and related industries.
14
<PAGE>
ITEM 7. FINANCIAL STATEMENTS -
Index to Financial Statements
BCAM International, Inc. and subsidiaries (the "Company"):
Report of Independent Auditors..................................... F-1
Consolidated balance sheet--December 31, 1997...................... F-2
Consolidated statements of operations--
Years ended December 31, 1997 and 1996............................. F-3
Consolidated statements of common shareholders' equity--
Years ended December 31, 1997 and 1996............................. F-4
Consolidated statements of cash flows--
Years ended December 31, 1997 and 1996 ............................ F-5
Notes to consolidated financial statements........................F-6-F-21
Drew Shoe Corporation (the "Predecessor"):
Report of Independent Auditors -
For the period from January 1, 1997 to September 22, 1997.............F-22
Report of Independent Auditors -
For the year ended December 31, 1996..................................F-23
Statements of Operations -
For the period from January 1, 1997 to September 22, 1997
and for the year ended December 31, 1996..............................F-24
Statements of Cash Flows -
For the period from January 1, 1997 to September 22, 1997
and for the year ended December 31, 1996..............................F-25
Notes to Financial Statements....................................F-26-F-29
15
<PAGE>
Report of Independent Auditors
Shareholders and Board of Directors
BCAM International, Inc.
We have audited the accompanying consolidated balance sheet of BCAM
International, Inc., as of December 31, 1997, and the related consolidated
statements of operations, shareholders' equity and cash flows for each of the
two years in the period ended December 31, 1997. These financial statements are
the responsibility of the Company's management. Our responsibility is to express
an opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the consolidated financial position of BCAM
International, Inc. at December 31, 1997, and the consolidated results of their
operations and their cash flows for each of the two years in the period ended
December 31, 1997, in conformity with generally accepted accounting principles.
/s/Ernst & Young LLP
Melville, New York
April 20, 1998
F-1
<PAGE>
BCAM International, Inc. and subsidiaries
Consolidated Balance Sheet
December 31, 1997
<TABLE>
<CAPTION>
<S> <C>
Assets
Current assets:
Cash and cash equivalents $ 1,594,000
Accounts receivable, less allowance for doubtful accounts of $120,000 1,584,000
Inventory 6,278,000
Prepaid expenses and other current assets 205,000
Current assets of discontinued operations, principally receivables 253,000
------------
Total current assets 9,914,000
Property, plant and equipment, at cost:
Land and buildings 826,000
Equipment, furniture and fixtures 2,924,000
Leasehold improvements 51,000
------------
3,801,000
Less accumulated depreciation and amortization (832,000)
------------
2,969,000
Deferred finance costs, net 786,000
Other assets 508,000
------------
Total assets $ 14,177,000
============
Liabilities and shareholders' equity
Current liabilities:
Current portion of long-term debt $ 463,000
Accounts payable 962,000
Accrued expenses and other current liabilities 1,637,000
Current liabilities of discontinued operations, principally trade payables 136,000
------------
Total current liabilities 3,198,000
Long-term debt and convertible notes, net of current maturities
and unamortized debt discount 7,972,000
Other non-current liabilities 295,000
Minority interest 618,000
Commitments and contingencies
Shareholders' equity:
Acquisition preferred stock, 750,000 authorized shares, none issued
Preferred Stock, 2,000,000 authorized, none issued
Common stock, par value $.01 per share -- 65,000,000 shares authorized,
18,171,641 shares issued and 17,408,459 shares outstanding 182,000
Paid-in surplus 26,338,000
Unamortized charge for beneficial debt conversion (4,290,000)
Deficit (19,237,000)
Less 763,182 treasury shares (899,000)
------------
Total shareholders' equity 2,094,000
------------
Total liabilities and shareholders' equity $ 14,177,000
============
</TABLE>
See accompanying notes.
F-2
<PAGE>
BCAM International, Inc. and subsidiaries
Consolidated Statements of Operations
For the years ended December 31, 1997 and 1996
1997 1996
----------- -----------
Revenues
Sales $ 3,932,000 $ --
License revenue 27,000 29,000
----------- -----------
Total 3,959,000 29,000
Cost of revenues 2,330,000 (56,000)
----------- -----------
Gross profit 1,629,000 85,000
Selling, general and administrative 2,991,000 1,408,000
Research and development 322,000 --
----------- -----------
Loss from operations (1,684,000) (1,323,000)
----------- -----------
Other Income (Expense)
Interest and financing costs (613,000) --
Charge for beneficial debt conversion (1,635,000) --
Interest income 60,000 54,000
----------- -----------
Total (2,188,000) 54,000
Minority interests charge for beneficial subsidiaries
preferred stock conversion (788,000) --
----------- -----------
Loss from continuing operations (4,660,000) (1,269,000)
Discontinued operations, including estimated loss on
disposal of approximately $50,000 in 1997 (1,376,000) (245,000)
----------- -----------
Net loss $(6,036,000) $(1,514,000)
=========== ===========
Net Loss per share:
Continuing operations $ (0.29) $ (0.08)
Discontinued operations (0.09) (0.02)
----------- -----------
Net loss per share $ (0.38) $ (0.10)
=========== ===========
Weighted average shares outstanding 16,071,000 14,868,000
=========== ===========
See accompanying notes
F-3
<PAGE>
BCAM International, Inc. and subsidiaries
Consolidated Statements of Common Shareholders' Equity
<TABLE>
<CAPTION>
Common Stock $.01 par Unamortized
value Charge for
----------------------- Paid-in Beneficial Debt
Shares Amount Surplus Conversion Deficit
------ ------ ------- ---------- -------
<S> <C> <C> <C> <C> <C>
Balance at January 1, 1996 15,620,415 156,000 15,034,000 -- (11,687,000)
Exercise of common stock warrants 22,500 -- 21,000 -- --
Registration and issuance costs -- -- (96,000) -- --
Net loss -- -- -- -- (1,514,000)
----------------------------------------------------------------------
Balance at December 31, 1996 15,642,915 156,000 14,959,000 -- (13,201,000)
Shares issued in January 1997 Placement 1,075,000 11,000 1,064,000 -- --
Issuance costs of January 1997 Placement -- -- (46,000) -- --
Beneficial conversion feature of
subsidiary preferred stock -- -- 788,000 -- --
10 % / 13 % Convertible Notes:
Est. fair value of detachable warrants -- -- 1,872,000 -- --
Est. fair value of beneficial conversion 5,925,000 (5,925,000)
Shares issued in acquisition of Drew Shoe 375,000 4,000 446,000 -- --
Shares issued and options granted in
connection with Drew Shoe acquisition
financing 347,500 3,000 967,000 -- --
Acquisition financing costs -- -- (275,000) -- --
Amortization of beneficial debt conversion -- -- -- 1,635,000 --
Consultant stock options -- -- 175,000 --
Conversion of subsidiary preferred 706,226 8,000 435,000 -- --
Exercise of options 25,000 -- 28,000 -- --
Net loss -- -- -- -- (6,036,000)
----------------------------------------------------------------------
Balance at December 31, 1997 18,171,641 $ 182,000 $26,338,000 (4,290,000) $(19,237,000)
======================================================================
<CAPTION>
Shares held
in
Subtotal Treasury Total
-------- -------- -----
<S> <C> <C> <C>
Balance at January 1, 1996 3,503,000 (899,000) 2,604,000
Exercise of common stock warrants 21,000 -- 21,000
Registration and issuance costs (96,000) -- (96,000)
Net loss (1,514,000) -- (1,514,000)
-------------------------------------
Balance at December 31, 1996 1,914,000 (899,000) 1,015,000
Shares issued in January 1997 Placement 1,075,000 -- 1,075,000
Issuance costs of January 1997 Placement (46,000) -- (46,000)
Beneficial conversion feature of
subsidiary preferred stock 788,000 -- 788,000
10 % / 13 % Convertible Notes:
Est. fair value of detachable warrants 1,872,000 -- 1,872,000
Est. fair value of beneficial conversion
Shares issued in acquisition of Drew Shoe 450,000 -- 450,000
Shares issued and options granted in
connection with Drew Shoe acquisition
financing 970,000 -- 970,000
Acquisition financing costs (275,000) (275,000)
Amortization of beneficial debt conversion 1,635,000 -- 1,635,000
Consultant stock options 175,000 -- 175,000
Conversion of subsidiary preferred 443,000 -- 443,000
Exercise of options 28,000 -- 28,000
Net loss (6,036,000) -- (6,036,000)
-------------------------------------
Balance at December 31, 1997 $ 2,993,000 $(899,000) $ 2,094,000
=====================================
</TABLE>
See accompanying notes.
F-4
<PAGE>
BCAM International, Inc. and subsidiaries
Consolidated Statements of Cash Flows
Year ended December 31
1997 1996
-------------------------
Operating activities
Net loss $(6,036,000) $(1,514,000)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation and amortization 212,000 190,000
Amortization of unamortized charge for
beneficial debt conversion 1,635,000
Amortization of deferred finance costs
and debt discount 151,000
Non-cash minority interest charge 788,000
Charge for compensatory consultant stock options 175,000
Changes in operating assets and liabilities:
Accounts receivable 337,000 186,000
Inventory (99,000)
Current assets of discontinued operations (56,000)
Accounts payable, accrued expenses and
other current liabilities 248,000 (239,000)
All other operating assets and liabilities (120,000) (18,000)
-------------------------
Net cash used in operating activities (2,765,000) (1,395,000)
-------------------------
Investing activities
Cash paid for purchase of shares of Drew Shoe (3,882,000)
Cash paid for costs to acquire Drew Shoe (476,000) (33,000)
Purchases of property, plant and equipment (151,000) (6,000)
Investment in software technology (151,000)
Proceeds from sale of held-to-maturity securities 1,507,000
-------------------------
Net cash provided by (used) in investing activities (4,509,000) 1,317,000
-------------------------
Financing activities
Proceeds from sale of common stock and warrants 1,075,000
Proceeds from sale of convertible preferred
stock of subsidiary 1,200,000
Proceeds from sale of 10%/13% Convertible Notes
and Warrants 6,000,000
Proceeds, net, from new bank financing arrangement
at Drew Shoe 1,135,000
Payment of existing debentures due to former Drew
Shoe shareholders (845,000)
Proceeds from note payable and drawdown on
line of credit 754,000 400,000
Repayment of note payable (450,000) (400,000)
Net proceeds from exercise of stock options 28,000 21,000
Cash paid for deferred finance, stock issuance
and registration costs (555,000) (119,000)
-------------------------
Net cash provided by (used) in financing activities 8,342,000 (98,000)
-------------------------
Increase (Decrease) in cash and cash equivalents 1,068,000 (176,000)
cash and cash equivalents at beginning of year 526,000 702,000
=========================
Cash and cash equivalents at end of year $ 1,594,000 $ 526,000
=========================
Supplemental disclosure:
Cash interest paid $ 110,000 -0-
=========================
See accompanying notes
F-5
<PAGE>
BCAM International, Inc. and subsidiaries
Notes to Consolidated Financial Statements
December 31, 1997
1. Description of Business and Principles of Consolidation
BCAM International, Inc. and subsidiaries (the "Company") has been primarily a
software technology and consulting company, specializing in providing ergonomic
solutions (human factors engineering) to individuals, major corporations and
government. On September 22, 1997, the Company acquired Drew Shoe Corporation
("Drew Shoe"), a designer, marketer, manufacturer and distributor of medical
footwear. Drew Shoe had revenues for its year ended December 31, 1996 of
approximately $14.6 million and has been in business for approximately 125
years.
The Company's revenues have historically been derived primarily from ergonomic
consulting services. In December 1997 the Board of Directors of the Company
decided to discontinue the operations of the ergonomic consulting services
business due to the inability of that business to generate operating profits for
the Company. In February 1998, the Board of Directors of the Company decided to
discontinue the operations of the HumanCAD software division as a result of the
lack of available financing to further the necessary business development
activities of that division on a basis that would enhance shareholder value.
Since the acquisition of Drew Shoe, the Company's revenues in the near term are
expected to be derived principally from the medical footwear business. The
Company's strategic focus is on building its presence in the medical footwear
and related industries and on broadening and strengthening the development and
commercialization of the Company's proprietary technologies, principally
Intelligent Surface Technology ("IST") and its proprietary "microvalve".
Because of the significance of Drew Shoe's operations to the ongoing operations
of the Company, Drew Shoe is considered a "predecessor" of the Company.
The consolidated financial statements include the accounts of BCAM
International, Inc. and its subsidiaries, principally Drew Shoe (medical
footwear), since September 22, 1997, BCAM Technologies, Inc. (principally IST
and related technologies), BCA Services, Inc. (principally human ergonomics
consulting which has been discontinued), and HumanCAD Systems, Inc. (principally
software development and marketing which has been discontinued).
The Company requires additional capital to fund its activities in 1998 and made
a private placement of its equity securities in April 1998 in order to satisfy
this need (see note 7). In April 1998, the Company and the holders of its
10%/13% Convertible Notes agreed to a restructuring of the obligation which
accelerates repayment to April 1999, among other matters discussed in Note 6.
2. Summary of Significant Accounting Policies
Cash Equivalents, Financial Instruments and Concentration of Credit Risk
The Company considers all highly liquid investments with a maturity of three
months or less when purchased to be cash equivalents. Financial instruments that
potentially subject the Company to concentrations of credit risk consist
principally of cash and trade accounts receivable. The Company maintains its
cash in bank deposit accounts that, at times, may exceed Federally insured
limits. Concentrations of credit risk with respect to trade receivables are
limited due to the large number of customers comprising the Company's customer
base, their dispersion across different geographic areas, and generally short
payment terms. In addition, the Company routinely assesses the financial
strength of its customers.
Use of Estimates
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the amounts reported in the financial statements and footnotes. Actual
results could differ from those estimates.
Revenue
Revenue from wholesale medical footwear sales is recognized at the time products
are shipped. Revenue from retail medical footwear sales through Company-owned
retail operations is recognized at the point of sale. License revenues are
recorded when earned under the related license agreement.
Inentory
F-6
<PAGE>
BCAM International, Inc. and subsidiaries
Notes to Consolidated Financial Statements
December 31, 1997
Inentories are stated at the lower of cost, determined on a first-in, first-out
basis, or market.
Property, Plant and Equipment
Property and equipment are stated at cost. Depreciation is calculated using the
straight-line method over the estimated useful lives of the assets.
Other Assets
The costs of acquiring or processing (principally professional and government
fees) patents, trademarks and other intellectual properties are capitalized at
cost. This amount is being amortized using the straight-line method over the
estimated useful lives of the underlying assets of approximately 5 years.
Research and Development
Research and development costs are charged to operations in the period incurred.
Income Taxes
The Company accounts for income taxes using Financial Accounting Standards Board
("FASB") Statement No. 109, "Accounting for Income Taxes." At December 31, 1997,
the Company has net operating loss carryforwards of approximately $15,937,000
for income tax purposes, expiring through 2012.
At December 31, 1997 and 1996, deferred tax assets approximating $5,886,000 and
$4,672,000, respectively, arising from the future potential availability of net
operating loss carryforwards have been offset in full by valuation allowances in
accordance with FASB Statement No. 109.
The utilization of these losses to reduce future income taxes will depend on the
generation of sufficient taxable income prior to the expiration of the net
operating loss carryforwards. Additionally, based on ownership changes which
occurred in 1997 and in prior years, it is expected that the annual utilization
of the otherwise available net operating loss carryforwards will be limited by
the provisions of Sections 382 and 383 of the Internal Revenue Code, as amended.
As such the Company may be restricted as to the utilization of its net operating
loss. The Company believes that significant issuances of additional stock could
trigger an additional change and a new limitation.
Net Loss Per Share
In March 1997, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Standards ("SFAS") No. 128, Earnings per Share. Statement
128 replaced the calculation of primary and fully diluted earnings per share
with basic and diluted earnings per share. Unlike primary earnings per share,
basic earnings per share excludes any dilutive effects of options, warrants and
convertible securities. Diluted earnings per share is very similar to the
previously reported fully diluted earnings per share. Net loss per share has
been computed on the basis of the weighted average number of common shares
outstanding. Common stock equivalents have been excluded because their effect is
antidilutive. There was no effect to the Company's financial statements of
adopting SFAS 128.
Stock-Based Compensation
In 1996, the Company adopted SFAS No. 123, "Accounting for Stock-Based
Compensation." In accordance with the standard, the Company elected to continue
to account for its stock-based compensation under Accounting Principles Board
Opinion No. 25, "Accounting for Stock Issued to Employees" and related
interpretations (APB 25). Under APB 25, because the exercise price of the
Company's stock options granted equals the market price of the underlying stock
on the date of the grant, no compensation expense is required to be recognized
except in the case of options issued which are subject to shareholder approval
(see Note 7).
F-7
<PAGE>
BCAM International, Inc. and subsidiaries
Notes to Consolidated Financial Statements
December 31, 1997
Reclassification
Certain amounts in the 1996 financial statements have been reclassified to
conform with the 1997 presentation.
3. Inventories
Inventories consisted of the following at December 31, 1997:
Raw materials $ 760,000
Work in process 976,000
Finished goods 4,542,000
----------
Total $6,278,000
==========
Inventories at September 22, 1997 (date of acquisition of Drew Shoe) were
approximately $6,175,000.
4. Property and equipment
Property and equipment consists of the following at December 31, 1997 and were
depreciated and amortized utilizing the estimated useful lives indicated below:
Range of
Estimated December
Useful Lives 31, 1997
------------ --------
Land $ 100,000
Buildings and improvements 10-35 years 726,000
Equipment, furniture and fixtures 5-10 years 2,924,000
Leasehold improvements 2-5 years 51,000
----------
Total 3,801,000
Less accumulated depreciation 832,000
----------
Total $2,969,000
----------
Approximately $2,839,000, net of accumulated depreciation and amortization, of
the total property and equipment was acquired in September 1997 as part of the
acquisition of Drew Shoe.
5. Acquisition of Drew Shoe
Effective September 22, 1997, the Company acquired all of the outstanding Common
Stock of Drew Shoe for approximately $4.7 million plus the assumption of
liabilities. The purchase price was paid by delivery to the shareholders of Drew
Shoe of an aggregate of $3,882,000 in cash, promissory notes in the aggregate
principal amount of $400,000 (See Note 6) and by delivery of an aggregate of
375,000 unregistered shares of the Company's Common Stock (valued at
approximately $1.20 per share to reflect a discount for lack of registration).
The promissory notes bear interest at 8% per annum, are due on September 19,
1999, and are payable in twenty-four (24) equal monthly installments aggregating
$8,333.34 (plus interest) with final payments due in the twenty-fifth (25th)
month aggregating $200,000.
See Note 6 for a description of the securities issued in order to finance the
acquisition of Drew Shoe.
Simultaneously with the acquisition, Drew Shoe entered into a credit facility
with a commercial bank (guaranteed by the Company) which is further described in
Note 6.
F-8
<PAGE>
BCAM International, Inc. and subsidiaries
Notes to Consolidated Financial Statements
December 31, 1997
Drew Shoe is a designer, manufacturer, marketer and distributor of medical
footwear headquartered in Lancaster, Ohio. In addition, Drew Shoe operates 15
retail shoe specialty stores. The Company has accounted for its acquisition of
Drew Shoe under the purchase method of accounting. Under such method, the
purchase price paid plus costs of the acquisition are allocated to the assets
and liabilities of the acquired company based on the estimated fair value of
assets and liabilities acquired. The remaining amount, if any, is allocated to
goodwill. The results of operations of the acquired company are consolidated
with the Company's operations beginning on the date of purchase. At December 31,
1997, a preliminary estimate of the fair value of assets and liabilities has
been made based upon certain appraisals and other data that is preliminary and
subject to change. Based upon such preliminary evaluation at December 31, 1997,
approximately $21,000 of goodwill has been recorded in connection with the
acquisition of Drew Shoe.
The following summary shows the unaudited pro-forma results of operations for
the years ended December 31, 1997 and 1996 assuming that the Company had
purchased Drew Shoe as of the beginning of each period shown. This information
gives effect to the increased interest and financing costs (excluding certain
material non-recurring charges that are discussed in Notes 6 and 7) and the
amortization of fair value adjustments (principally for increased depreciation).
The Company has not included a provision for income taxes because it believes
that it will have sufficiently available net operating losses available to
offset anticipated profits from Drew Shoe. This summary may not be indicative of
what the actual results of operations would have been had the purchase occurred
at the beginning of each period shown.
1997 1996
---- ----
Revenues $15,083,000 $14,638,000
=========== ===========
Loss from operations $(1,019,000) $(1,123,000)
=========== ===========
Loss from Continuing Operations (excluding
non-recurring charges in 1997) (3,365,000) (2,506,000)
=========== ===========
Net loss (excluding non-recurring charges in
1997) (4,741,000) (2,751,000)
=========== ===========
Net loss per share (excluding non recurring
charges in 1997) (0.30) (0.19)
=========== ===========
6. Long Term Debt and Convertible Notes
Secured bank debt - Simultaneously with the acquisition of Drew Shoe, the
Company through its wholly-owned subsidiary, Drew Shoe, entered into a credit
facility with a commercial bank consisting of: (i) a revolving line of credit up
to $4,500,000 (which is based upon agreed upon percentages of accounts
receivable and inventory) and (ii) a term loan of $1,000,000. As of the date of
the Drew Shoe acquisition, the Company believes there was approximately
$4,500,000 available under this credit facility (approximately $3,750,000 of
which was drawn down to pay certain existing liabilities of Drew Shoe, including
an existing liability to that bank of approximately $2,655,000, debentures
payable to former shareholders of approximately $845,000, and to transfer
$250,000 to the Company). The revolving line of credit matures on September 30,
1999, and calls for current payments of interest at a rate of prime plus 1.5%
(10% at December 31,1997). The term loan portion of the credit facility (in the
principal amount of $1,000,000) also bears an interest rate of prime plus 1.5%
(10% at December 31, 1997) and is payable in monthly installments through
September 30, 2000 with a payment due at that time of $583,000. Both the
revolving line of credit and term loan may be used for general working capital
purposes and are guaranteed by the Company. The credit facility with this bank
requires Drew Shoe to maintain compliance with certain financial covenants,
principally net worth, and contains restrictions on the transfer of cash to the
Company.
F-9
<PAGE>
BCAM International, Inc. and subsidiaries
Notes to Consolidated Financial Statements
December 31, 1997
Costs incurred in connection with the bank term loan and revolving credit
totaling approximately $75,000, are included in Deferred finance cost and are
being amortized to Interest and financing cost using the effective interest
method over a two year period.
10%/13% Convertible Notes and Warrants - In order to fund the acquisition of
Drew Shoe and provide working capital to the Company, on September 19, 1997, the
Company issued subordinated convertible notes (the "Convertible Notes"), and
Non-Redeemable Class DD Warrants, in the aggregate amount of $6,000,000. The
Convertible Notes are due, as amended, on April 16, 1999 unless at any time
after September 19, 1998 they are converted, at $.80 per share, into 7,500,000
shares of Common Stock of the Company. Such conversion feature is subject to
antidilution provision in certain circumstances including the issuance of Common
Stock and warrants in 1998 discussed below. The Convertible Notes bear an
interest rate of 10%, payable semi-annually, but the Company, at its discretion,
may pay interest in the form of additional Convertible Notes in which case the
annual interest rate becomes 13% with semi-annual compounding. The Convertible
Notes require the Company to maintain compliance with certain financial
covenants including maintenance of minimum levels of interest coverage and net
worth (as defined). At December 31, 1997, the Company was in violation of such
covenants. On April 14, 1998, the noteholders and the Company entered into the
First Amendment of the Note Purchase Agreement (together with a Stock Pledge
Agreement and Security Agreement) in order to restructure the agreement. The key
elements of the restructuring are as follows: (1) waiving of the Company's
violations of the financial covenants at December 31, 1997 (as well as certain
other breaches of the agreement) (2) eliminating the financial covenants through
April 16, 1999, (3) securing the obligation with a pledge of all of the assets
of the Company (excluding the assets of Drew Shoe which are already pledged to a
bank), including the stock of the Company's subsidiaries, (4) accelerating the
maturity date for the obligation from September 19, 2002 to April 16, 1999, (5)
cancellation of Class DD warrants to purchase 400,000 shares of common stock of
the Company, (6) issuance to the holders a total of 10% of the common shares of
the Company's subsidiaries Drew Shoe Corporation and BCAM Technologies, Inc. As
a result of the restructuring, the Company has a significant capital requirement
to repay this obligation ($6,000,000) in approximately one year or face default
and possible foreclosure on the security. It is the Company's intention to
refinance or otherwise restructure this obligation. The Company expects to take
a significant charge to operations in 1998 in connection with the finalization
of the restructuring of the debt.
The Non-Redeemable Class DD Warrants entitle the holders to purchase, as
amended, 2,000,000 shares of common stock at $1.75 per share at any time prior
to September 19, 2002. The Company has, under generally accepted accounting
principles, recorded approximately $1,872,000 of the $6,000,000 received from
the sale of the Convertible Notes and Warrants as the estimated value (based
upon a "Black Scholes" calculation) of the detachable warrants issued in
connection with the Convertible Notes resulting in a discount to the value
assigned to the Convertible Notes. Such amount is being amortized over the
five-year term of the Convertible Notes.
The private placement of convertible notes and warrants to one investor group
(aggregating $5,000,000 of the total $6,000,000) was made with the assistance of
an investment banker who charged a cash fee of 6% ($300,000) plus 187,500
unregistered shares of common stock (valued at $1.20 per share to reflect a
discount for lack of registration), and Class EE warrants to purchase 500,000
shares of common stock at an exercise price of $0.80 per share, of the Company.
The cash fee, shares of stock and the estimated fair value of the warrants
aggregate approximately $1,025,000. This amount has been apportioned between
Deferred financing costs, and acquisition costs of Drew Shoe. The portion
allocated to Deferred financing costs (approximately $775,000), together with
legal and other costs of the transaction are being amortized over the five year
term of the Convertible Notes. There were no investment banking fees associated
with the remaining $1,000,000 of proceeds.
The market value of the Company's common stock on the Nasdaq SmallCap market on
the date of the transaction was approximately $1.50.
In response to positions recently taken by the Securities and Exchange
Commission, Emerging Issues Task Force Statement D-60 has been issued. Statement
D-60 requires certain new accounting for securities issued which are convertible
into common stock at a value which is "beneficial" at the date of issuance (such
as the Convertible Notes described above and the Convertible Preferred Stock of
BCA Services, Inc., a subsidiary of the Company, described in Note 7). This
accounting requires that the beneficial value be charged to operations (based
upon the traded market price, without discount, compared to the conversion
price) in the case of a convertible note or to retained earnings as a dividend
in the case of a preferred stock, over a period reflecting the shortest period
in which the investor has to exercise and under the most favorable terms to the
investor. As such, the Company has charged approximately $5,925,000
(representing the value of the beneficial debt conversion feature of the
Convertible Notes measured at the date of issuance) to Unamortized Charge for
Beneficial Debt Conversion in the shareholders' equity section of its
Consolidated Balance Sheet. Such amount is being charged to Interest and
financing costs in the Consolidated Statements of Operations at the rate of
approximately $1,481,000 per quarter until September 19, 1998. See, however, the
discussion of the restructuring of this financing below. This charge to
operations is considered a non-recurring charge in the preparation of the
summary pro-forma data contained in Note 5. This charge is in addition to
amortization of Deferred financing costs and the debt discount related to the
Convertible Notes (approximately $1,872,000), over the five-year term of the
Convertible Notes.
F-10
<PAGE>
BCAM International, Inc. and subsidiaries
Notes to Consolidated Financial Statements
December 31, 1997
At December 31, 1997, long term debt consists of the following:
10%/13% Convertible Notes, face amount
$6,000,000, net of approximately $1,767,000
of unamortized debt discount with interest
payable on March 19 and September 19, due
April 16, 1999 unless earlier converted $4,233,000
Revolving credit arrangement with a bank,
payable on September 30, 1999, bearing
interest at prime plus 1.5 % 2,618,000
Term Loan agreement with a bank, bearing
interest at prime plus 1.5% payable in
monthly principal installments of $11,905
plus interest through September 30, 2000 when
the final payment of $583,000 is due. 976,000
Notes payable to sellers of Drew Shoe
(including $187,500 payable to the ongoing
President of Drew Shoe), bearing interest at
8%, with monthly payments of principal
aggregating $8,333 plus interest and balloon
payments aggregating $200,000 on September
19, 1999 375,000
Amount payable to parties related to former
owners and an officer of Drew Shoe due December
31, 1998, bearing interest at prime 214,000
Other, net 19,000
----------
Total long term debt 8,435,000
less: current portion 463,000
----------
$7,972,000
==========
Principal payment requirements on the above obligations, adjusted for the debt
restructure described above is approximately as follows subsequent to December
31, 1997:
Years ended Amount
-----------
1998 $ 463,000
1999 9,049,000
2000 690,000
-----------
10,202,000
F-11
<PAGE>
BCAM International, Inc. and subsidiaries
Notes to Consolidated Financial Statements
December 31, 1997
Less unamortized debt discount (1,767,000)
-----------
Total Long-term Debt at December 31, 1997 $ 8,435,000
-----------
7. Shareholders' Equity
1997 Sale of Convertible Preferred Stock of Subsidiary - On July 22, 1997,
September 8 and September 18, 1997, BCA Services, Inc. ("BCA"), previously
wholly-owned by the Company, sold 120 shares of BCA's Convertible Preferred
Stock (the "Preferred Stock") for an aggregate consideration of $1,200,000 in
two private offerings to accredited investors.
The Preferred Stock is convertible into shares of the Company's common stock at
a price equal to a fixed discount (30%) of the average closing bid price of the
common stock over a period of time ending on the day preceding the conversion
date and subject to a ceiling price.
In addition, for 100 of the shares of Preferred Stock sold, the Company issued
Non-Redeemable Class BB Warrants to purchase 50,000 shares of common stock at
$0.72 per share. For 20 shares of Preferred Stock sold, the Company issued
Non-Redeemable Class CC Warrants to purchase 10,000 shares of common stock at
$1.03 per share. The Class BB and CC Warrants have a term of five years and the
underlying common stock has been registered by the Company.
The two private placements of BCA Preferred Stock were made with the assistance
of a placement agent. The placement agent charged a commission of 8% in fees and
2% in expenses, plus warrants to purchase 50,000 shares of common stock of the
Company at approximately $0.72 per share for five years, for the first offering
($1,000,000). The placement agent charged 6% in fees and no warrants for the
second offering ($200,000).
At December 31, 1997, $500,000 of the Preferred Stock had been converted into
706,226 common shares of the Company at a weighted average conversion price of
approximately $0.71. Subsequent to December 31, 1997, the remaining $700,000 of
the Preferred Stock has been converted into 1,066,585 shares of common stock at
$0.66 per share resulting in the transfer of $618,000 of minority interest at
December 31, 1997 into shareholders equity.
See Note 6 for a discussion of certain accounting treatment called for by
Emerging Issues Task Force Statement D-60. Because the Preferred Stock issued is
that of a subsidiary, but is convertible into shares of the Company, the Company
has recorded the Preferred Stock of the subsidiary as "Minority interest" in the
consolidated financial statements until its conversion into common stock of the
Company. The "beneficial" conversion feature, therefore, has been charged to
Minority interests (approximately $788,000) in the accompanying Consolidated
Statement of Operations. Such amount is considered a non-recurring charge in
preparation of the summary pro forma data in Note 5.
1997 Sale of common stock and warrants of the Company - In January 1997, the
Company commenced an offering and ultimately sold 1,075,000 equity units (each
consisting of one share of the Company's common stock and one non-redeemable
Class AA warrant) for $1,075,000. The Class AA warrants, as amended, entitle the
holder to purchase one share of the Company's Common Stock at $0.65 per share
until March 31, 2002.
Authorized shares/Shares reserved for future issuance - At the annual meeting of
shareholders on February 19, 1998 (including an adjournment to March 16, 1998),
the shareholders of the Corporation approved an increase in the authorized
shares of common stock from 40,000,000 shares to 65,000,000 shares.
Additionally, the shareholders approved the adoption of changes to the bylaws of
the Corporation to, among other matters, permit the Board of Directors to issue
up to 2,000,000 shares of Preferred Stock of the Company on terms to be set by
the Board of Directors.
The Company is also authorized to issue up to 750,000 shares of its acquisition
preferred stock, $.01 par value, none of which are presently issued and
outstanding. The acquisition preferred stock is permitted to be issued pursuant
to (i) a
F-12
<PAGE>
BCAM International, Inc. and subsidiaries
Notes to Consolidated Financial Statements
December 31, 1997
statutory merger or consolidation in which the Company is the surviving entity,
(ii) the acquisition by the Company of substantially all the assets or business
of another entity or (iii) the acquisition by the Company of 50% or more of the
voting securities of another entity. The Board of Directors is authorized to
fix, before issuance, the voting powers, designations, preferences and other
rights, qualifications, limitations and restrictions applicable to each series
of acquisition preferred stock.
Common shares reserved for future issuance as of December 31, 1997, adjusted in
the case of the 1998 stock option plan for the February 1998 increase to the
shares available under such plan, are approximately as follows:
Units sold in public offering in 1990:
F-13
<PAGE>
BCAM International, Inc. and subsidiaries
Notes to Consolidated Financial Statements
December 31, 1997
Class B warrants, subject to antidilution (see below) 1,292,000
Class E warrants, subject to antidilution (see below) 737,000
Unit Options, expired in 1997 0
Conversion feature of 10%/13% Convertible Notes, subject
to antidilution and "pay in kind" provisions ($0.80, 2002
see Note 6) 7,500,000
Conversion feature of BCA Preferred stock, stated at amount
actually converted in full prior to March 31, 1998, (see
above) 1,067,000
Third party options (see table below) 1,050,000
1989 Stock Option Plan (see below) 432,000
1989 Nonstatutory Plan (see below) 25,000
1995 Stock Option Plan (as amended in 1998, see below) 8,000,000
Warrants issued in private placements:
Class C warrants, expired during 1997 0
Class D warrants, expired during 1997 0
Class AA warrants ($0.65, 2002, see above) 1,075,000
Class BB warrants ($0.72, 2002, see above) 25,000
Class CC warrants ($1.03, 2002, see above) 10,000
Class DD warrants ($1.75, 2002, see above) 2,400,000
Class EE warrants ($0.80, 2002 see Note 6) 500,000
----------
24,113,000
==========
Class B and Class E Warrants - The Company's Class B warrants were issued in
connection with a 1990 public offering of securities of the Company. The Class E
Warrants were issued in connection with a "Discounted Warrant Plan" offered to
holders of the Class A Warrants (all of which have been exercised or expired)
and Class B Warrants issued in connection with the public offering in 1990. The
Class B and Class E Warrants are presently exercisable, were due to expire in
January 1998, have been extended to October 17, 1998 and are subject to
anti-dilution provisions. As a result of the financings completed in 1997, the
anti-dilution provisions of the warrants were triggered and resulting in the
following revisions to the warrant price and the number of shares subject to
warrant:
<TABLE>
<CAPTION>
Exercise price Number of shares Exercise price Number of shares
-------------- ---------------- -------------- ----------------
per warrant per warrant per share subject to warrant
----------- ----------- --------- ------------------
<S> <C> <C> <C> <C>
Class B Warrants:
- -----------------
Previous $1.50 1.2 $1.25 969,191
Current $1.14 1.6 $ .71 1,292,254
Class E Warrants:
- -----------------
Previous $1.25 1.1 $1.14 540,747
Current $0.95 1.5 $ .63 737,382
</TABLE>
The 1998 private placement discussed in the following paragraphs may trigger the
operation of antidilution provisions of the Class B and Class E warrants and
will trigger the operation of the antidilution provisions of the 10%/13%
Convertible Notes discussed in Note 6.
1998 Private placement of common shares and warrants
Beginning on April 14, 1998, the Company commenced a private offering of its
common stock and warrants. The offering contemplates aggregate proceeds of
$2,000,000 for the purchase of 1,980,198 shares of common stock of the Company
and warrants to purchase 250,000 shares of common stock at $2.05 for three years
by seven accredited investors. Through April 16, 1998 the Company issued
1,881,188 shares of common stock, together with warrants to purchase 237,500
common shares at $2.05 per share for three years, to private investors in
exchange for $1,900,000, less $475,000 held in escrow pending the Company's
filing of a registration statement covering the shares and shares underlying the
warrants prior to June 13, 1998. The Company has agreed to register such shares
and has agreed to penalties of 3% per month should the registration statement
not be declared effective within 130 days.
The number of shares issuable to these investors will be "repriced" pursuant to
a schedule initially in $300,000 increments (4) and then in $200,000 increments
(4) on eight occasions commencing with the effectiveness of a registration
statement covering the shares and again 60 days later and then in 30 day
intervals. On such dates, the investor would receive the additional number of
shares, if any, that result from the difference between the number of shares
actually issued and the number of shares which would have been issued using a
23% discount to the market price, as defined, at that time. The operation of
this provision could result in significantly greater number of shares being
issued. The investors have agreed not to sell any shares before at least 120
days after the closing. The Company is exposed to significant penalties for
failure to have a registration statement declared effective covering such shares
within 130 days, has agreed not to issue certain financings and has agreed to
pay a placement agent a 6.5% fee in connection with the transaction.
F-14
<PAGE>
BCAM International, Inc. and subsidiaries
Notes to Consolidated Financial Statements
December 31, 1997
Stock Options
In June 1995, the shareholders of the Company approved the adoption of the 1995
Stock Option Plan (the "1995 Plan"). The 1995 Plan supercedes and closes all
prior option plans and provides for the granting of incentive stock options
("ISOs") and/or nonqualified stock options to employees, directors or
consultants of the Company to purchase an aggregate of 2,000,000 shares of the
Company's common stock. The option price per share for ISOs granted under the
1995 Plan shall not be less than the fair market value of the Company's common
stock on the date of grant. Options vest and are exercisable over various
periods up to ten years from the date of grant. No option may be granted under
the 1995 Plan after June 2005. At December 31, 1996, there were 219,500 shares
available for granting of future options.
In 1997, the Company issued option grants under the 1995 Plan to purchase an
aggregate of 3,984,000 shares of Common Stock of the Company, approximately
3,764,500 of which were subject to approval by shareholders of an amendment to
the Company's 1995 Plan. The amendment, approved at the 1997 Annual Meeting of
Shareholders in February 1998, increases the number of shares under the 1995
Plan from 2,000,000 to 8,000,000 shares.
In 1989, the shareholders of the Company approved the adoption of a 1989 Stock
Option Plan (the "1989 Plan"). The 1989 Plan provided for the granting of
incentive stock options and/or nonqualified stock options to key employees and
consultants to purchase shares of the Company's common stock at a price per
share not less than the fair market value on the date of grant. In 1992, the
Plan was amended to: (a) increase the number of shares to 1,565,957, (b) permit
the granting of nonqualified stock options at a price per share less than the
fair market value of the Company's common stock on the date of grant and (c)
permit options to be exercised up to two years after termination of employment
under certain circumstances. Options vest and are exercisable over various
periods up to six years from the date of grant.
In 1989, the Company also adopted a Nonstatutory Stock Option Plan (the "1989
Nonstatutory Plan") for directors. Under the 1989 Nonstatutory Plan, the Company
could grant options for the purchase of an aggregate of 355,000 shares of common
stock at not less than fair market value at the date of grant. Pursuant to the
terms of the 1995 Plan, no options may be granted under the 1989 Plan or the
1989 Nonstatutory Plan subsequent to June 22, 1995.
Option activity during each of the two years ended December 31, 1997 for the
1989 Plan and the 1989 Nonstatutory Plan is summarized as follows:
F-15
<PAGE>
BCAM International, Inc. and subsidiaries
Notes to Consolidated Financial Statements
December 31, 1997
<TABLE>
<CAPTION>
1989 Nonstatutory Plan 1989 Plan
Shares Under Option Shares Under Option
--------------------------------------------------------------
Weighted
Number Average Number
Option price of Option price per Exercise of
per share Shares share Price Shares
--------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Balance at January 1, 1996 100,000 452,000
Exercised -- $0.92 (2,500)
Cancelled/expired -- $0.92 to $3.13 $2.18 (17,500)
-------
Balance at December 31,1996 100,000 $1.94 432,000
Exercised $1.13 (25,000) --
Cancelled/expired $1.10 to $1.13 (50,000) --
------- -------
Balance at December 31,1997 25,000 $1.94 432,000
======= =======
</TABLE>
Option activity during each of the two years ended December 31, 1997 for the
1995 Plan is summarized as follows:
1995 Plan
Shares Under Option
--------------------------------------------------
Weighted Number
Option price per Average of
share Exercise Price shares
--------------------------------------------------
Balance at January 1, 1996 $1.04 1,932,500
Granted $0.95 to $1.20 $1.09 193,000
Cancelled/expired $0.92 $1.09 (350,000)
Exercised $0.92 $0.92 (20,000)
---------
Balance at December 31, 1996 $1.04 1,755,500
---------
Granted $0.75 to $1.52 $1.09 3,984,000
Cancelled/expired $0.92 to $1.68 $1.17 (55,000)
---------
Balance at December 31,1997 5,684,500
=========
Of the options issued in 1997, options to purchase approximately 3,684,500
shares were issued subject to approval of the Company's shareholders. Such
approval was received in February 1998. Generally accepted accounting principles
require that a charge to compensation expense be made if the market value of the
stock on the date of shareholder approval exceeds the market value on the date
of grant. The closing bid price of the Company's common stock on the date of the
shareholder vote was approximately $1.41. Options to purchase approximately 1.8
million shares were granted at prices that, although fair market value at the
time of grant, were lower than $1.41. As a result, the Company will record a
charge to compensation expense of approximately $1,200,000 in the first quarter
of 1998.
Primarily as a result of the acquisition activity of the Company, 550,000 fully
vested nonstatutory stock options were granted to eight investment bankers and
other vendors who, as third parties, are outside of the 1995 Plan, as amended.
The options are exercisable for from two to ten years, 375,000 shares at a price
of $0.75 per share and 175,000 shares at a price of $1.52 per share.
During 1996, the Company granted 100,000 fully vested nonstatutory stock options
at fair market value to a third party, which are exercisable for a period of ten
years at a price of $1.17 per share. In addition, during 1995, the Company
granted 300,000 fully vested nonstatutory stock options at fair market value to
a third party, which are exercisable for a
F-16
<PAGE>
BCAM International, Inc. and subsidiaries
Notes to Consolidated Financial Statements
December 31, 1997
period of eighteen months at a price of $1.05 per share, and 5,000 nonstatutory
stock options at fair market value to a third party, which were cancelled in
1996. Further, in 1994 the Company granted 100,000 nonstatutory stock options at
fair market value to a third party, which vest ratably over two years and are
exercisable for a period of five years at a price of $1.69 per share. At
December 31, 1997, 1,050,000 of these options are outstanding.
The following table summarizes information about the options to third parties
(1,050,000) and warrants not reflected as granted as part of any option plan.
Options/warrants
Outstanding
----------------------------------------------------------
Weighted Average
Range of Number Outstanding at Remaining Weighted Average
Exercise Price December 31, 1997 Contractual Life Exercise Price
--------------------------------------------------------------------------
$0.65 to $1.00 2,787,382 3.2 years $0.77
$1.01 to $1.75 4,377,254 3.4 years $1.50
==========================================================================
$0.65 to $1.75 7,164,636 3.3 years $1.22
==========================================================================
The Company recorded a charge to selling, general and administrative costs of
approximately $175,000 for the year ended December 31, 1997 related to the
estimated fair value of the options granted to consultants.
* * * * * * * *
Pro forma information regarding net income and earnings per share is required by
FASB Statement No. 123, "Accounting for Stock-Based compensation" which requires
that the information be determined as if the Company has accounted for its stock
options granted subsequent to December 31, 1994 under the fair value method of
that statement. The fair value for these options was estimated at the date of
the grant using a Black-Scholes option pricing model. The Company's pro forma
information follows:
December 31,
1997 1996
----------- -----------
Pro forma net loss:
Continuing operations $(4,995,000) $(1,617,000)
Discontinued operations (1,376,000) (245,000)
----------- -----------
Total $(6,371,000) $(1,862,000)
=========== ===========
Pro forma net loss per share:
Basic
Continuing operations $ (.31) $ (.11)
Discontinued operations (.09) (.02)
----------- -----------
$ (.40) $ (.13)
=========== ===========
Assuming dilution
Continuing operations $ (.32) (.11)
Discontinued operations (.09) (.02)
----------- -----------
$ (.41) $ (.13)
=========== ===========
The fair value of these options at the date of the grant was estimated with the
following weighted average assumptions for 1997 and 1996: risk free interest
rates ranging from 6.25% to 6.36%, no dividend yield, volatility factor of the
expected market price of the Company's common stock ranging from 49% to 76%, and
a weighted average expected life of the options ranging from six to ten years.
Because Statement 123 is applicable only to options granted subsequent to
December 31, 1994 and employee stock options granted vest over a period from one
to four years, its pro forma effect will not be fully reflected in pro forma net
loss.
The following table summarizes information about stock options, including those
to third parties, outstanding at December 31, 1997:
Options Outstanding Options Exercisable
-------------------------------- --------------------
Weighted
Number Average Weighted Number Weighted
- -----------------------------------------------------------------------
F-17
<PAGE>
BCAM International, Inc. and subsidiaries
Notes to Consolidated Financial Statements
December 31, 1997
Outstanding at Remaining Average Outstanding Average
Range of December 31, Contractual Exercise at December Exercise
Exercise Price 1997 Life Price 31, 1997 Price
----------------------------------------------------------------------------
$0.75-$1.00 2,950,500 8.06 years $0.78 1,465,083 $0.78
$1.01-$2.00 4,033,000 7.5 years $1.33 1,614,750 $1.21
$2.01-$3.22 208,000 1.3 years $2.65 207,000 $2.65
----------------------------------------------------------------------------
$0.75-$3.22 7,191,500 7.5 years $1.14 3,286,833 $1.11
============================================================================
The weighted average fair value of all stock options granted in 1997 was $.63
per share.
8. Discontinued Operations
Ergonomic Consulting Services Division - In December 1997, the Board of
Directors of the Company approved a plan to sell the operations of its Ergonomic
Consulting Services Division ("ECSD"). ECSD has not generated operating profits
and is no longer considered a core asset in light of the Company's current
strategy. The plan of disposition involved finding a strategic buyer who would
take over the Company's contractual commitments (some of which are long-term) to
consulting division customers and liquidating the remaining assets through
collection (with respect to receivables) or sale or disposal (with respect to
furniture and equipment). On February 9, 1998, the Company closed on the sale of
the revenue contract rights and transfer of the obligations for certain related
personnel of the ECSD to a third party. Terms of the sale call for the payment
of a portion of future revenues of the contracts sold as well as a portion of
certain follow-on work, or referrals for work provided by the Company. At
December 31, 1997, assets of the ECSD were approximately, 155,000, consisting
principally of billed and unbilled receivables, and liabilities were
approximately $76,000 consisting principally of trade payables. The operations
of the ECSD from January 1, 1998 through disposal on February 9, 1998 did not
generate a loss due to the high utilization of personnel on contracts during
that time. Approximately $50,000 has been accrued in the December 31, 1997
financial statements as a loss on disposal representing management's estimate of
the write-off of furniture and equipment and accrual of certain lease costs.
There was no material severance paid in connection with the discontinuance of
the ECSD. Revenues, gross margin and net loss for ECSD are approximately the
following for the years ended December 31, 1997 and 1996:
1997 1996
---- ----
Revenues $ 467,000 $ 576,000
Gross Margin $ 183,000 $ 247,000
Net Loss $(356,000) $(245,000)
HumanCAD Systems Operations - During late February 1998, as a result of
specific events at the time, the Board of Directors of the Company approved a
plan to seek alternative value for the HumanCAD Systems operations ("HCAD") by
(i) initially reducing the activity and (ii) seeking a strategic or management
buyer for the operation.
In December 1997, the Company had reached agreement with a funding source to
provide approximately $2.5 million for development and marketing of the
Company's existing and planned HCAD ergonomic modeling software products. In
January 1998, the Company commenced executing the business plan contemplated by
the financing but in late February 1998, the funding source advised the Company
that they were no longer willing to go forward with the planned financing. The
Company is seeking a strategic or possible management buyer for a majority of
HCAD.
The measurement date for the discontinuance is February 1998, at which time
losses from January 1, 1998 through February 1998 will be recorded and a
provision for discontinued operations (principally severance and non-cancellable
lease costs) will be made. Such amount is expected to exceed $500,000. The
Company has reflected the 1997 operations of HCAD as a discontinued operation in
the December 31, 1997 financial statements. At December 31, 1997, assets of the
HCAD were approximately $98,000 consisting principally of customer
receivables, certain computer and communications equipment, furniture, and
inventory. Liabilities were approximately $60,000 consisting principally of
trade payables and payroll. Revenues, gross margin and net loss for HCAD are
approximately the
F-18
<PAGE>
BCAM International, Inc. and subsidiaries
Notes to Consolidated Financial Statements
December 31, 1997
following for the year ended December 31, 1997 (HCAD did not operate in 1996):
1997
----
Revenues $ 135,000
Gross Margin $ 125,000
Net Loss $(1,000,000)
9. Commitments and contingencies
Leases - The Company leases its office space for a term extending through March
31, 2000. In August, 1996, this lease was modified to reflect a reduction in
leased space. Additionally, the Company has entered into various operating
leases for equipment. Future minimum payments under noncancellable operating
leases for years ending December 31 are as follows:
1998 $541,000
1999 406,000
2000 256,000
2001 77,000
Thereafter 88,000
Rent expense in 1997 and 1996, under all operating leases, was approximately
$550,000 and $179,000, respectively.
Collective bargaining agreement - Approximately 155 of Drew Shoe's approximately
255 employees are covered by a collective bargaining agreement with a union. The
contract covering such employees is due to expire in May 1998.
Litigation - In January 1998, a third party filed suit against the Company's
Drew Shoe subsidiary alleging that it is due a fee of not less than $297,000 in
connection with the Company's acquisition of Drew Shoe. Drew Shoe disputes this
claim and the Company intends to vigorously defend this action. There are no
other material legal proceedings pending against the Company.
10. Pension
The Company has two noncontributory, defined benefit pension plans covering
substantially all employees. Benefits under the plan covering nonunion employees
are based on average monthly compensation and years of service. Benefits under
the plan covering union employees are based on years of service. The Company's
policy is to make contributions to the plans sufficient to meet minimum funding
requirements. Effective September 3, 1997, the Company's non-union plan was
frozen and no future benefits will accrue to participants in the plan. The net
pension liability at December 31, 1997 reflects the result of these plan
changes.
A summary of the components of net periodic pension cost for the period from
September 22, 1997 to December 31, 1997 is as follows:
Service cost $ 9,000
Interest 33,000
Actual return on plan assets (14,000)
Amortization and deferral (4,000)
--------
Net pension cost $ 24,000
========
F-19
<PAGE>
BCAM International, Inc. and subsidiaries
Notes to Consolidated Financial Statements
December 31, 1997
The following table sets forth the funded status and amounts recognized in the
Consolidated Balance Sheet as of December 31, 1997:
Actuarial present value of benefit obligation:
Vested benefit $1,525,000
Nonvested benefits 70,000
----------
Accumulated and projected benefit obligation 1,595,000
Plan assets at fair market value 1,056,000
----------
Accumulated benefit obligations in excess of
plan assets 539,000
Accrued pension cost $ 539,000
Significant assumptions used in the accounting for the defined benefit plans
were as follows:
Discount rate 7.00%
Expected long-term rate of return on assets 8.25%
The plans assets are invested in an annuity investment fund, certificates of
deposit, insurance contracts and interest bearing cash accounts.
11. Other
Other assets- Other noncurrent assets principally include patent costs of
approximately $147,000 (net of related amortization of approximately $61,000),
intangible pension assets (approximately $106,000) and cash surrender value of
life insurance (approximately $88,000). Goodwill (preliminary) in connection
with the Drew acquisition is included in other assets and totals approximately
$21,000.
Other non-current liabilities- Other non-current liabilities consist principally
of accrued pension cost and certain non-current obligations under contracts and
commitments in connection with the acquisition of Drew Shoe.
Costs of financings not completed- In the third quarter of 1997, the Company was
able to secure more favorable acquisition financing and credit facility for its
acquisition of Drew Shoe than it had originally expected. As a result, the
Company elected not to complete a proposed acquisition financing and a proposed
credit facility. Costs associated with such uncompleted financings of
approximately $130,000 were charged to Interest and financing costs in the year
ended December 31, 1997.
Charges to fourth quarter operations - Significant charges to operations in the
fourth quarter of 1997 include: (i) approximately $175,000 for the estimated
value of options granted to consultants in May and September 1997, (ii) accrual
of contractual management bonuses for three executives of approximately $75,000
(including $25,000 related to discontinued operations), (iii) write off of
approximately $75,000 of capitalized software costs no longer considered
realizable (included in discontinued operations) and (iv) costs of approximately
$235,000 related to a collaborative research effort (microvalve) and certain
software development costs.
F-20
<PAGE>
BCAM International, Inc. and subsidiaries
Notes to Consolidated Financial Statements
December 31, 1997
Advertising expense - Advertising expense for Drew Shoe were approximately
$125,000 for the period of inclusion of Drew Shoe in the Company's financial
statements for 1997. Such costs are expensed as incurred.
Significant customer - One customer accounts for approximately 11% of the
Company's revenues for the year ended December 31, 1997. This information is not
meaningful for the year ended December 31, 1996 due to the level of revenue and
the discontinued operations.
F-21
<PAGE>
REPORT OF INDEPENDENT AUDITORS
To the Stockholder
Drew Shoe Corporation
We have audited the accompanying statements of operations and cash flows of DREW
SHOE CORPORATION for the period from January 1, 1997 to September 22, 1997.
These financial statements are the responsibility of the Company's management.
Our responsibility is to express an opinion on these financial statements based
on our audit.
We conducted our audit in accordance with generally accepted auditing standards.
Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audit provides a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the results of operations and cash flows of Drew Shoe
Corporation for the period from January 1, 1997 to September 22, 1997, in
conformity with generally accepted accounting principles.
/s/ ERNST & YOUNG LLP
Melville, New York
March 15, 1998
F-22
<PAGE>
REPORT OF INDEPENDENT AUDITORS
To the Stockholder
Drew Shoe Corporation
We have audited the accompanying statements of operations and cash flows of DREW
SHOE CORPORATION for the year ended December 31, 1996. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audit.
We conducted our audit in accordance with generally accepted auditing standards.
Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audit provides a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the results of operations and cash flows of Drew Shoe
Corporation for the year ended December 31, 1996, in conformity with generally
accepted accounting principles.
/s/ J.H. COHN LLP
Roseland, New Jersey
September 26, 1997
F-23
<PAGE>
DREW SHOE CORPORATION
STATEMENTS OF OPERATIONS FOR THE PERIOD FROM
JANUARY 1, 1997 THROUGH SEPTEMBER 22, 1997
AND THE YEAR ENDED DECEMBER 31, 1996
January 1, 1997 through Year Ended
September 22, 1997 December 31, 1996
------------------ -----------------
Net sales $11,124,000 $14,609,000
Cost of goods sold 6,657,000 9,147,000
----------- -----------
Gross profit 4,467,000 5,462,000
----------- -----------
Operating expenses:
Selling 2,690,000 3,477,000
General and administrative 1,358,000 1,700,000
----------- -----------
Totals 4,048,000 5,177,000
----------- -----------
Operating income 419,000 285,000
----------- -----------
Interest expense (261,000) (338,000)
Interest and other income 33,000 79,000
----------- -----------
Net income $ 191,000 $ 26,000
=========== ===========
See Notes to Financial Statements.
F-24
<PAGE>
DREW SHOE CORPORATION
STATEMENTS OF CASH FLOWS FOR THE PERIOD FROM
JANUARY 1, 1997 THROUGH SEPTEMBER 22, 1997
AND THE YEAR ENDED DECEMBER 31, 1996
<TABLE>
<CAPTION>
January 1, 1997 through Year Ended
September 22, 1997 December 31, 1996
------------------ -----------------
<S> <C> <C>
Operating activities:
Net income 191,000 $ 26,000
Adjustments:
Depreciation and amortization 188,000 248,000
Changes in operating assets and liabilities:
Accounts receivable (512,000) 433,000
Inventories 316,000 (712,000)
Prepaid expenses and other (236,000) 25,000
Accounts payable 235,000 26,000
Accrued expenses (104,000) 120,000
--------- ---------
Net cash provided by operating activities 78,000 166,000
--------- ---------
Investing activities:
Purchases of property and equipment (118,000) (266,000)
(Increase) decrease in cash value of life
insurance and other (19,000) 59,000
--------- ---------
Net cash used by investing activities (137,000) (207,000)
--------- ---------
Financing activities:
Net proceeds under revolving note agreement 852,000 218,000
Proceeds from long-term debt -- 24,000
Principal payments on long-term debt (628,000) (146,000)
Distributions to shareholders (60,000) (56,000)
--------- ---------
Net cash provided by financing activities 164,000 40,000
--------- ---------
Net increase (decrease) in cash 105,000 (1,000)
Cash, beginning of period 27,000 28,000
--------- ---------
Cash, end of period $ 132,000 $ 27,000
========= =========
Supplemental disclosure of cash flow data:
Interest paid $ 259,000 $ 329,000
========= =========
Supplemental disclosure of noncash investing
and financing information:
Change in additional pension liability:
Increase (decrease) in intangible pension asset $ 106,000 $(237,000)
Increase in stockholders' equity (51,000) (180,000)
--------- ---------
Totals $ 55,000 $(417,000)
========= =========
</TABLE>
See Notes to Financial Statements.
F-25
<PAGE>
Note 1 - Business and summary of accounting policies:
Business:
Drew Shoe Corporation (the "Company") designs, manufactures,
imports, markets and distributes women's and men's shoes for sale to
independent retailers and through Company-owned retail operations
throughout the United States.
Basis of accounting/Use of estimates:
The accompanying financial statements are prepared on the historical
basis of accounting of the Company prior to its acquisition, on
September 22, 1997, by BCAM International, Inc. ("BCAM"). Results of
operations and cash flows on the historical basis of accounting may
not be indicative of future results of operations. This is because,
among other factors, the additional depreciation, amortization or
other charges which may result from the revaluation of the assets
and liabilities of the Company in connection with the acquisition.
Further, the recording of other acquisition adjustments, as well as
future events and conditions, may affect comparisons.
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates
and assumptions that affect certain reported amounts and
disclosures. Accordingly, actual results could differ from those
estimates.
Financial instruments and off-balance-sheet risk:
Financial instruments that potentially subject the Company to
concentrations of credit risk consist principally of cash and trade
accounts receivable. The Company maintains its cash in bank deposit
accounts that, at times, may exceed Federally insured limits.
Concentrations of credit risk with respect to trade receivables are
limited due to the large number of customers comprising the
Company's customer base, their dispersion across different
geographic areas, and generally short payment terms. In addition,
the Company routinely assesses the financial strength of its
customers.
Inventories:
Inventories are stated at the lower of cost, determined on a
first-in, first-out basis, or market.
Property and equipment:
Property and equipment are stated at cost. Depreciation is
calculated using the straight-line method over the estimated useful
lives of the assets.
Goodwill:
Goodwill, included in other assets, is amortized on a straight-line
basis over periods ranging from five to twenty years.
Revenue recognition:
Revenue from wholesale product sales is recognized at the time
products are shipped. Revenue from retail product sales through
Company-owned retail operations is recognized at the point of sale.
Income taxes:
The Company has elected to be treated as an "S" Corporation under
the applicable sections of the Internal Revenue Code. Under these
sections, corporate income or loss, in general, is allocated to the
stockholders for inclusion in their personal income tax returns.
Accordingly, there is no provision for Federal income taxes in the
accompanying financial statements.
The Company has also elected to be treated as an "S" Corporation in
the states in which it files corporate income tax returns.
Accordingly, no provision for state income taxes has been provided
in the accompanying financial statements.
Advertising:
F-26
<PAGE>
The Company expenses the cost of advertising as incurred.
Advertising costs charged to operations were approximately $321,000
and $364,000 for the period from January 1, 1997 through September
22, 1997 and for the year ended December 31, 1996, respectively.
Note 2 - Inventories:
Inventories used in the computation of cost of goods sold were
approximately $6,378,000 and $6,694,000 at September 22, 1997 and December
31, 1996, respectively.
Note 3 - Property and equipment:
Property and equipment consists of the following at September 22, 1997 and
December 31, 1996, respectively, and were amortized utilizing the
estimated useful lives indicated below:
Range of
Estimated September December
Useful Lives 22, 1997 31, 1996
------------ -------- --------
Land $ 100,000 $100,000
Building and improvements 10-35 years 857,000 865,325
Machinery and equipment 5-13 years 2,742,000 2,614,715
---------- ----------
Total 3,699,000 3,580,040
Less accumulated depreciation 2,397,000 2,229,895
---------- ----------
Total 1,302,000 $1,350,145
---------- ----------
Note 4 - Notes payable - and long term debt:
Charges for interest included in the accompanying Statements of Operations
and Cash Flows are based principally upon the following historical
borrowings of the Company:
<TABLE>
<CAPTION>
Approximate
Weighted Average
Borrowings
----------------
To
September
22, 1997
--------
<S> <C>
Revolving credit (prime) and Bankers Acceptance
($500,000 at 7.25%) facility with a Bank $2,164,000
Mortgage Note payable with interest at prime plus .25 375,000
Notes payable to related party with interest at prime 214,000
Debentures payable to related parties with interest
at 10% 845,000
All other 25,000
----------
Total $3,623,000
==========
</TABLE>
The Revolving Credit and Banker Acceptance facility, Mortgage Notes and
Debentures were repaid on September 22, 1997 in connection with the
acquisition by BCAM.
Interest charged to the Statement of Operations for related parties
approximated $108,000 and $119,000 in the period ended September 22, 1997
and the year ended December 31, 1996.
Principal payment requirements on the above obligations, as adjusted for
the refinancing discussed in Note 9, in each of the five years subsequent
to December 31, 1997 are as follows:
Year Ending
December 31, Amount
------------ ------
1998 $ 148,000
1999 2,980,000
2000 694,000
2001 2,000
2002 2,000
F-27
<PAGE>
Note 5 - Pension plans:
The Company has two noncontributory, defined benefit pension plans
covering substantially all employees. Benefits under the plan covering
nonunion employees are based on average monthly compensation and years of
service. Benefits under the plan covering union employees are based on
years of service. The Company's policy is to make contributions to the
plans sufficient to meet minimum funding requirements. Effective September
3, 1997, the Company's non-union plan was frozen and no future benefits
will accrue to participants in the plan. The net pension liability at
December 31, 1997 reflects the result of these plan changes with no
material curtailment gain or loss.
A summary of the components of net periodic pension cost for the period
from January 1, 1997 to September 22, 1997 and for the year ended December
31, 1996 is as follows:
1997 1996
-------- --------
Service cost $ 28,000 $136,000
Interest 100,000 144,000
Actual return on plan assets (40,000) (46,000)
Amortization and deferral (13,000) (13,000)
-------- --------
Net pension cost $ 75,000 $221,000
======== ========
Significant assumptions used in the accounting for the defined benefit
plans were as follows:
Discount rate 7.00%
Expected long-term rate of return on assets 8.25%
Effective September 3, 1997, the accrual of future benefits under the
nonunion defined benefit pension plan was suspended. The effect of the
curtailment of the nonunion plan on the Company's financial statements at
December 31, 1996 cannot currently be determined.
Note 6 - Commitments and other matters:
Lease commitments:
The Company leases retail space and certain machinery and equipment
under operating leases that expire through 2003. Related rent
expense amounted to approximately $269,000 and $369,000 for the
period from January 1, 1997 through September 22, 1997 and for the
year ended December 31, 1996, respectively.
Future minimum rental payments required under the noncancelable
operating leases in years subsequent to December 31, 1997 are as
follows:
Year Ending
December 31, Amount
------------ ------
1998 $390,000
1999 251,000
2000 100,000
2001 38,000
2002 28,000
Collective bargaining agreement:
At September 22, 1997, approximately 60% of the Company's workforce
is represented under a collective bargaining agreement which expires
May 31, 1998.
Concentrations:
The Company relies to a large extent on medical footwear for sales.
Approximately 60% of the Company's sales are women's shoes. One
customer accounts for more than approximately 11% of the Company's
sales.
Note 7 - Provision for income taxes:
A reconciliation of income taxes based on pre-tax income and the Federal
statutory rate to the Company's effective
F-28
<PAGE>
rate for the period from January 1, 1997 through September 22, 1997 and the year
ended December 31, 1996 follows:
Period ended Year ended
September December
22, 1997 31, 1996
-------- --------
Federal statutory income tax rate 34.0% 34.0%
Increase (decrease) resulting from:
State income taxes, net of Federal
tax benefit 7.8 7.0
"S" Corporation income not subject
to Federal or state tax (48.6) (42.7)
Other 6.8 1.7
---- ---
Effective rate -- % -- %
==== ====
Note 8 - Unaudited proforma income tax information:
Unaudited proforma income tax information as if the Company had been a "C"
Corporation subject to Federal and state income taxes follows:
Period ended Year ended
September December
22, 1997 31, 1996
-------- --------
Income before income
taxes $191,000 $ 26,000
Pro forma provision
for income taxes (73,000) (10,000)
-------- --------
Pro forma net income $118,000 $ 16,000
======== ========
Note 9 - Subsequent events:
Effective September 22, 1997, the Company's stockholders sold all of the
outstanding common stock of the Company to BCAM International, Inc.
("BCAM"), a publicly-held software technology and consulting company, for
cash and other consideration.
On September 22, 1997, the Company entered into a new $4,500,000 revolving
credit facility and a $1,000,000 term loan with the Bank. Under the terms
of the revolving credit facility, the Company may borrow a maximum of 80%
of eligible accounts receivable, as defined, and 35% of eligible
inventory, as defined. Such borrowings bear interest at the prime rate
plus 1.5%, payable monthly. Principal payments are not required under the
revolving credit facility until expiration on September 30, 1999.
Borrowings under the revolving credit facility and the term loan are
secured by substantially all of the Company's assets and guaranteed by
BCAM.
The agreement contains various restrictive covenants including net worth
requirements, limitations on dividends and distributions, limitations on
transactions with affiliates, as defined, and the maintenance of a debt
service coverage ratio.
F-29
<PAGE>
ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
Not applicable.
PART III
ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS, COMPLIANCE
WITH SECTION 16(A) OF THE EXCHANGE ACT
Directors and Executive Officers
As of April 10, 1998, the directors and executive officers of BCAM
International, Inc. ("the Company") are as follows:
Name Class Age Position with Company
- ---- ----- --- ---------------------
Michael Strauss I 56 Chairman, President, Chief Executive Officer
and Director
Robert P. Wong I 56 Vice Chairman, Chief Technology Officer and
Director
Norman B. Wright II 61 Vice Chairman, President and Chief Executive
Officer, HumanCAD(R) Systems and Director
Charles G. Schuyler 50 President and Chief Executive Officer of Drew
Shoe Corporation (a subsidiary of the Company)
Kenneth C. Riscica 44 Vice President - Finance, Chief Financial
Officer, Treasurer and Secretary
Joel L. Gold II 56 Director
Glenn F. Santmire III 54 Director
Mark L. Plaumann I 42 Director
Stephen Savitsky III 52 Director
The Company's directors have historically been elected by the Company's
stockholders at each annual meeting or, in the case of a vacancy, were appointed
by the directors then in office, to serve until the next annual meeting or until
their successors are elected and qualified. Officers are appointed by and serve
at the discretion of the Board of Directors. At the 1997 Annual Meeting of
Stockholders, held on February 19, 1998, the stockholders approved a resolution
providing for the staggered election of members of the Board of Directors. The
Company has elected to group the Directors into three classes, with each class
to serve for a three year period. In that manner, the shareholders benefit from
continuity and experience of the Directors. The Directors are grouped into Class
I, Class II and Class III. In the first year of such classifications, it is
necessary to stagger the period of service of the Classes. Thereafter, members
of each Class would serve for three years. Therefore, Class I Directors serve
for a three year period ending with the annual meeting of shareholders following
the year ended December 31, 1999, Class II Directors serve for two years until
the annual meeting following the year ended December 31, 1998 and the Class III
Directors serve for one year until the next annual meeting of the shareholders
16
<PAGE>
Michael Strauss became the Company's President and Chief Operating Officer
effective January 2, 1995 and its Chairman of the Board and Chief Executive
Officer on February 16, 1995. From 1991 to December 31, 1994, Mr. Strauss was
President and Chief Operating Officer of Colorado Prime Corp., a home food
service company providing home delivery of high quality, custom designed food
programs to retail customers. From 1984 to 1991, he was Chairman and Chief
Executive Officer of Capital Credit Corporation, a subsidiary of Union
Corporation, a New York Stock Exchange Company. Capital Credit Corporation
provides receivables management and consumer debt collection services to
corporations in the financial services, telecommunications, health care and
related businesses. Prior to his tenure at Union Corporation, Mr. Strauss was
employed by American Express Company in various senior management positions
including Executive Vice President of the Financial Services Division of
Shearson Lehman Brothers, Executive Vice President of Travel Related Services,
and President of American Express Canada, Inc. Mr. Strauss has a BBA from the
City University of New York and an MBA from the Baruch School-City University of
New York.
Robert P. Wong was appointed Vice Chairman of the Board and Chief
Technology Officer in February 1995, after having become a director in February
of 1994. From September 1996 through October 15, 1997, Mr. Wong also served as
Acting Chief Financial Officer, Acting Secretary and Acting Treasurer.
Previously, from February 1994 through February 1995, Mr. Wong worked as a
representative for the Prudential Insurance Company, and was a private investor
from 1989 to February 1995. Over the previous 27 years, Mr. Wong was founder and
president of several technology companies and president of several subsidiaries
of Coordinated Apparel, Inc. Mr. Wong has an SB in Electrical Engineering and
also an SB in Industrial Management from Massachusetts Institute of Technology.
Norman B. Wright was appointed President and Chief Executive Officer of
the Company's HumanCAD Systems division and Vice-Chairman of the Board of
Directors of the Company in April of 1997. Previously, Mr. Wright was President
and Chief Executive Officer of Virtek Vision International, Inc., a
Canadian-based, multi-national laser-projection machine intelligence and pattern
analysis systems designer and manufacturer. Prior to that he has held senior
management posts in several companies and has launched and guided a number of
public software technology companies through their successful development.
Charles G. Schuyler was appointed a director in September of 1997 and
resigned as a director effective April 1, 1998. Mr. Schuyler is President and
Chief Executive Officer of Drew. Drew Shoe was acquired by the Company on
September 22, 1997. Mr. Schuyler commenced his employment with Drew Shoe in 1970
and became a 50% principal owner in 1982. Mr. Schuyler is a member of the
National Shoe Retailers Association, Pedorthic Footwear Association and Two/Ten
Foundation. Mr. Schuyler is a graduate of Ohio University majoring in Economics.
Kenneth C. Riscica joined the executive officers of the Company as Vice
President - Finance, Chief Financial Officer, Treasurer and Secretary effective
October 16, 1997. Mr. Riscica, formerly a partner in charge of an emerging
companies practice group with Arthur Andersen & Co. LLP (having been a partner
from 1987 to 1992 after joining the firm in 1976), more recently served as Chief
Executive Officer of Riscica Associates, Inc.,(1993-1997) a financial and
management consulting firm and as Chief Financial Officer of Magna-Lab, Inc., a
publicly traded medical technology company (1993 to 1997).
Joel L. Gold was elected a Director in February 1994. Since September
1997, Mr. Gold has served as Vice Chairman of Coleman and Company Securities
Inc., and Senior Managing Director of Interbank Capital Group, LLC. From April
1996 to September 1997, Mr. Gold was Executive Vice President of L.T. Lawrence
Co., an investment banking firm. From April 1995 to April 1996, Mr. Gold was a
managing director and head of investment banking at Fechtor & Detwiler. From
1993 to 1995, Mr. Gold was a managing director at Furman Selz Incorporated, an
investment banking firm. Prior to joining Furman Selz, from 1991 to 1993, he was
a managing director at Bear Sterns & Co., an investment banking firm.
Previously, Mr. Gold was a managing director at Drexel Burnham Lambert for
nineteen years. He is currently a member of the Board of Directors of Concord
Camera, Sterling Vision, Inc. and Life Medical Sciences, Inc. Mr. Gold has a law
degree from New York University and an MBA from Columbia Business School.
Glenn F. Santmire was appointed a director in October 1995. Since 1995 he
has been employed by Unisys Corporation as Group Vice President of the Worldwide
Services-Market Sector Group. From 1994 to 1995 he was President of GFS
Associates, Inc., a consulting firm which he founded. From 1992 to 1994 Mr.
Santmire was a Senior Vice President at Mastercard International and from 1990
to 1992 he was President of Enhanced Telephone Services, Inc.,
17
<PAGE>
a subsidiary of Citibank. Mr. Santmire possesses both a BA and an MBA degree
from New York University as well as a law degree from George Washington
University School of Law.
Mark L. Plaumann was appointed a director in September of 1997. Mr.
Plaumann has been a Senior Vice President of Wexford Management from January
1996 to March 1997 and is presently a consultant to that firm, and since March
1995 has been a director and/or Vice President of the general partner of various
public partnerships managed by Wexford Management. Mr. Plaumann joined the
predecessor entities of Wexford Management in February 1995. Prior to joining
Wexford Management, Mr. Plaumann was a Managing Director of Alvarez & Marsal,
Inc., a crisis management consulting firm, from 1990 to 1995, and from 1985 to
1990 he was with American Healthcare Management, Inc., an owner and operator of
hospitals, where he served in a variety of capacities, most recently as its
President. Prior to that he was with Ernst & Young LLP in its auditing and
consulting divisions for eleven years. Mr. Plaumann is a director of Wahlco
Environmental Systems, Inc., a manufacturer of environmental conditioning
systems.
Stephen Savitsky was appointed a director in October of 1997. Mr. Savitsky
is the Founder, Chairman of the Board of Directors and Chief Executive Officer,
since 1988, of Staff Builders, Inc., a large provider of temporary services to
the home healthcare industry in the United States. Mr. Savitsky has a BA in
Economics from Yeshiva University and an MBA in Marketing and Finance from
Baruch School of Business.
Compliance with Section 16(a) of the Securities Exchange Act of 1934
Section 16(a) of the Securities Exchange Act of 1934 requires the Company's
officers and directors and persons who own more than ten percent of a registered
class of the Company's equity securities (collectively, the "Reporting
Persons"), to file reports of ownership and changes in ownership with the
Securities and Exchange Commission and to furnish the Company with copies of
these reports. Based solely on the Company's review of the copies of such forms
received by it during the Company's fiscal year ended December 31, 1997, the
Company believes that the Reporting Persons complied with all filing
requirements applicable to them except with respect to Mr. Riscica who did not
timely file a Form 4 in connection with options to purchase 200,000 shares of
common stock granted to him in 1997.
ITEM 10. EXECUTIVE COMPENSATION
Directors' Compensation
Employee-directors receive no compensation for serving on the Board of
Directors other than reimbursement of expenses incurred in attending meetings.
Non-employee directors elected or appointed to the Board of Directors are paid
an annual director's fee of $5,000 plus $500 for each Board meeting attended and
are reimbursed for expenses incurred in attending meetings.
Executive Compensation
The table set forth below shows information concerning the compensation
for services in all capacities during the years indicated paid to or earned by
(i) the Company's Chief Executive Officer and (ii) each executive officer of the
Company (other than the Chief Executive) whose annual compensation exceeded
$100,000 during 1997.
18
<PAGE>
<TABLE>
<CAPTION>
Long Term
Annual Compensation Compensation Awards
------------------------------------ -------------------
Name and Principal Salary Bonus Other Annual Options All Other
Position Year ($) ($) Compensation ($) (#) Compensation ($)
- -------- ---- -------- -------- ---------------- --------- ----------------
<S> <C> <C> <C> <C> <C> <C>
Michael Strauss (1)
Chairman, President,
Chief Executive 1997 $225,000 $100,000 $9,000 2,000,000 --
Officer and Chief 1996 $200,000 -- $8,280 -- --
Operating Officer 1995 $200,000 -- $7,743 1,000,000 --
Robert P. Wong (2)
Vice Chairman and 1997 $127,000 $ 25,000 $6,000 750,000 --
Chief Technology 1996 $102,000 -- $6,000 -- --
Officer 1995 $ 87,000 -- $2,000 492,500 --
Norman Wright (3)
Vice Chairman and
Chief Executive 1997 $ 93,750 $ 25,000 $7000 750,000 --
Officer of the 1996 -- -- -- -- --
HumanCAD division 1995 -- -- -- -- --
</TABLE>
- ----------
(1) Mr. Strauss became employed by the Company as its President and Chief
Operating Officer on January 2, 1995 at an annual salary of $200,000. He
subsequently became Chairman and Chief Executive Officer on February 16,
1995
(2) Mr. Wong was elected a Director in February, 1994. He became employed by
the Company as its Chief Technology Officer, and was appointed Vice
Chairman, on February 16, 1995 at an annual salary of $84,000, which was
subsequently raised to $102,000. From September, 1996 through October 15,
1997, he also served as Acting Chief Financial Officer, Acting Secretary
and Acting Treasurer.
(3) Mr. Wright became Vice Chairman of the Board and President and Chief
Executive Officer of HumanCAD Systems Division in April 1997. Pursuant to
a consulting agreement effective April 7, 1997, and expiring April 7,
1999, unless renewed, Mr. Wright receives a basic consulting fee at a rate
of $125,000 per annum and a performance bonus of at least $25,000 per year
for the first two years.
Employment Agreements
Michael Strauss
Mr. Michael Strauss became the President and Chief Operating Officer of
the Company effective January 2, 1995 pursuant to an employment agreement dated
October 13, 1994 and amended on February 16, 1995. On February 16, 1995 Mr.
Strauss became the Chief Executive Officer and Chairman of the Board of
Directors. Pursuant to a revised employment agreement effective January 1, 1997,
and expiring December 31, 1999, unless renewed, Mr. Strauss receives a base
salary at a rate of $225,000 per year. Mr. Strauss shall be entitled to receive
a bonus, which amount for the period ending December 31, 1997 shall not exceed
$100,000 nor be less than $25,000. The amount of the bonus for the years ending
December 31, 1998 and December 31, 1999 shall be agreed to by Mr. Strauss and
the Company by December 31, 1997, and be based upon mutually agreed to
objectives for Mr. Strauss. Mr. Strauss is also entitled to participate in any
pension plans or bonus plans of the Company or of any subsidiary, which ever is
more beneficial to him, to be included in the Company's health, disability, life
insurance and other benefit plans, and to receive an allowance for the cost of
an automobile.
Mr. Strauss received, in addition to his salary and any bonus, (i) options
to purchase at the fair market value January 2, 1995, an aggregate of 300,000
shares of common stock of the Company, scheduled to vest and become
19
<PAGE>
exercisable for 100,000 shares on January 2, 1996, for 100,000 shares on January
2, 1997, and for 50,000 shares on January 2, 1998 and 1999, respectively; (ii)
options to purchase at the fair market value on February 16, 1995, an aggregate
of 200,000 shares of common stock of the Company, scheduled to vest and become
exercisable for 50,000 shares on February 16, 1996, 1997, 1998 and 1999
respectively; (iii) options to purchase at the fair market value on May 7, 1997,
an aggregate of 1,000,000 shares of common stock of the Company, scheduled to
vest and become exercisable 33 1/3% of such shares immediately, 33 1/3% of such
shares on January 2, 1998, and 33 1/3% of such shares on January 2, 1999, (iv)
options to purchase, at the fair market value on July 3, 1995, an aggregate of
500,000 shares of common stock of the Company, scheduled to vest and become
exercisable for 100,000 shares on each of the succeeding four anniversary dates,
and (v) options to purchase at the fair market value on September 17, 1997, an
aggregate of 1,000,000 shares of common stock of the Company, scheduled to vest
and become exercisable 33 1/3% of such shares on September 17,1998, 33 1/3% of
such shares on September 17, 1999, and 33 1/3% of such shares on September 17,
2000. All options granted hereunder shall be incentive stock options to the
extent they may qualify for such treatment.
Robert P. Wong
Mr. Robert P. Wong became Vice Chairman of the Board and Chief Technology
Officer of the Company effective February 16, 1995. Pursuant to an employment
agreement effective January 1, 1997, and expiring December 31, 1998, unless
renewed, Mr. Wong receives a base salary at a rate of $127,000 per annum. Mr.
Wong shall be entitled to receive a bonus, which amount for the period ending
December 31, 1997 shall not exceed $70,000 nor be less than $25,000. The amount
of the bonus for the year ending December 31, 1998 shall be agreed to by Mr.
Wong and the Company by December 31, 1997, and be based upon mutually agreed to
objectives for Mr. Wong. Mr. Wong is also entitled to participate in any pension
plans or bonus plans of the Company or of any subsidiary, which ever is more
beneficial to him, to be included in the Company's health, disability, life
insurance and other benefit plans, and to receive an allowance for the cost of
an automobile.
Mr. Wong received, in addition to his salary and any bonus, (i) option to
purchase at the fair market value on July 21, 1994 an aggregate of 7,500 shares
of common stock of the Company scheduled to vest and become exercisable on July
21, 1995; (ii) options to purchase at fair market value on February 16, 1995 an
aggregate of 200,000 shares of common stock of the Company, scheduled to vest
and become exercisable for 10,000 shares on August 16, 1995, for 51,250 shares
on February 16, 1996, for 51,250 shares on February 16, 1997, for 43,750 shares
on February 16, 1998, and for 43,750 shares on February 16, 1999; (iii) options
to purchase at the fair market value on June 22, 1995 an aggregate of 25,000
shares of common stock of the Company, scheduled to vest and be exercisable for
10,000 shares on June 22, 1995, for 7,500 shares on June 22, 1996, and for 7,500
shares on June 22, 1997; (iv) options to purchase at the fair market value on
July 3, 1995, an aggregate of 267,500 shares of common stock of the Company,
scheduled to vest and be exercisable for 66,875 shares on each of the succeeding
anniversaries of the grant, over four years; and (v) options to purchase at the
fair market value on May 7, 1997, an aggregate of 500,000 shares of common stock
of the Company, scheduled to vest and become exercisable 50% of such shares
immediately and 50% of such shares on January 2, 1998. Subsequently, on
September 17, 1997, he was granted on option to purchase 250,000 shares of
common stock of the Company, scheduled to vest and become exercisable, in equal
amounts on the anniversary of the grant, over three years. All options granted
hereunder shall be incentive stock options to the extent they may qualify for
such treatment.
Norman B. Wright
Mr. Norman B. Wright became Vice Chairman of the Board and President and
Chief Executive Officer of the HumanCAD Systems division in April 1997. Pursuant
to a consulting agreement effective April 7, 1997, and expiring April 7, 1999,
unless renewed, Mr. Wright receives a basic consulting fee at a rate of $125,000
per annum. Mr. Wright is entitled to receive a performance bonus on an annual
basis within 30 days of the end of the Company's fiscal year. The amount of such
bonus shall be fixed by the board of directors of the Company acting upon
recommendations from Management and its Compensation Committee, provided that
the minimum amount of incentive bonus payable to Mr. Wright in respect of each
of the first two years of the engagement will be not less than $25,000.00. Mr.
Wright is also entitled to receive an allowance for the cost of an automobile,
and will be reimbursed for the costs of maintaining a health plan, including a
term life insurance policy.
Mr. Wright received, in addition to his salary and any bonus, options to
purchase at the fair market value on May 7, 1997, an aggregate of 500,000 shares
of common stock of the Company, scheduled to vest and become exercisable 50% of
such shares immediately and 50% of such shares on April 7, 1998. Subsequently,
on September 17, 1997, he was granted on option to purchase 250,000 shares of
common stock of the Company, scheduled to vest and become exercisable, in equal
amounts on the anniversary of the grant, over three years. All options granted
hereunder shall be incentive stock options to the extent they may qualify for
such treatment.
Notwithstanding the fixed term of the engagement, the Company may
terminate the engagement of Mr. Wright at any time for cause including but not
limited to any material breach of the provisions of the agreement by Mr. Wright.
20
<PAGE>
ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth information as of March 31, 1998, based on
information obtained from the records of the Company with respect to the
beneficial ownership of shares of Common Stock of the Company by (i) each person
known by the Company to be owners of more than five percent of the outstanding
shares of Common Stock, (ii) each director and nominee and certain executive
officers, and (iii) all officers and directors as a group.
Common Stock
------------
<TABLE>
<CAPTION>
Amount and Nature Percentage of Common
Name and Address of Beneficial Owner of Beneficial Ownership(1) Stock Owned
------------------------------------ -------------------------- -----------
<S> <C> <C>
R. Weil & Associates (2) 1,234,500(6) 6.5%
Kirr, Marbach & Company LLC (2) 2,054,500(7) 10.9%
Kirr Marbach Group (2) 2,252,500(8) 11.9%
Austost Anstalt Schaau (3) 2,025,000(9) 10.8%
UFH Endowment Ltd. (3) 2,025,000(9) 10.8%
Impleo, LLC (4) 2,000,000(10) 11.2%
Wexford Management, LLC (4) 2,000,000(11) 11.2%
Wexford Special Situations 1997, LP (4) 1,250,600(12) 7.0%
Michael Strauss (5) 1,266,666(13) 7.1%
Robert P. Wong (5) 528,750(14) 3.1%
Norman B. Wright (5) 250,000(15) 1.5%
Joel L. Gold( 5) 107,500(16) *
Sandra Meyer (5) -0-(17) *
Glenn F. Santmire (5) 25,000(18) *
Charles Schuyler (5) 375,000 2.2%
Mark Plaumann (5) -0- *
Stephen Savitsky (5) -0- *
All officers and directors as a group (9 persons) 2,552,916 11.5%
</TABLE>
1 The Company believes that all persons named in the table have sole voting
and investment power with respect to all shares of Common Stock
beneficially owned by them.
2 Address is 621 Washington Street, Columbus, IN 47201.
3 Address is c/o L.H. Financial Services, 160 Central Park South, New York,
NY 10019.
4 Address is 411 West Putnam Avenue, Greenwich, CT 06830.
5 Address is c/o BCAM International, Inc., 1800 Walt Whitman Road, Melville,
New York 11747
6 Includes 320,000 shares issuable upon exercise of Non-Redeemable Class AA
Warrants and 62,000 shares issuable upon exercise of Non-Redeemable Class
DD Warrants.
7 Kirr Marbach & Company LLC, a registered investment advisor and the
managing general partner of the three Limited Partnerships (621 Partners,
Appleton Associates and R. Weil & Associates), has sole voting and
dispositive discretion with respect to securities held by the Limited
Partnerships, which include in the aggregate 700,000 shares issuable upon
exercise of Non-Redeemable Class AA Warrants and 122,000 shares issuable
upon exercise of Non-Redeemable Class DD Warrants.
8 Kirr Marbach & Co., LLC (as a general partner of the Limited
Partnerships), David M. Kirr, Terry B. Marbach and Gregg T. Summerville
may be deemed to constitute a group within the meaning of Regulation
13D-G. Beneficial ownership by this group include in the aggregate 700,000
shares issuable upon exercise of Non-Redeemable Class AA Warrants being
registered herein and 320,000 shares issuable upon exercise of
Non-Redeemable Class DD Warrants.
9 Includes 2,000,000 shares of Common Stock issuable upon the conversion of
50 shares of BCA Services, Inc.
21
<PAGE>
Preferred Stock being registered herein and 25,000 shares issuable upon
exercise of Non-Redeemable Class BB Warrants.
10 Impleo, LLC was organized for the purpose of investing in the Registrant.
The members of Impleo are Wexford Spectrum Investors, LLC, Wexford Special
Situations 1997, LP and Wexford Special Situations 1997 Institutional, LP.
Impleo has sole voting and dispositive discretion with respect to
securities held by these entities, which include, in the aggregate,
2,000,000 shares of Common Stock issuable upon exercise of Non-Redeemable
Class DD Warrants.
11 Wexford Management LLC, the manager of Impleo, LLC and Wexford Spectrum
Investors, LLC and the investment manager of Wexford Special Situations
1997, LP and Wexford Special Situations 1997 Institutional, LP, has sole
voting and dispositive discretion with respect to securities held by these
entities, which include, in the aggregate, 2,000,000 shares of Common
Stock issuable upon exercise of Non-Redeemable Class DD Warrants.
12 Include 1,250,600 shares of Common Stock issuable upon exercise of
Non-Redeemable Class DD Warrants.
13 Includes options to purchase 679,833 shares of Common Stock exercisable
within 60 days of the date hereof, plus options to purchase 586,833 shares
of Common Stock which will be exercisable within 60 days. Does not include
options to purchase 439,917 shares of Common Stock not exercisable within
60 days of the date hereof, and options to purchase 1,293,417 shares of
Common Stock not exercisable within 60 days.
14 Includes options to purchase 308,688 shares of Common Stock exercisable
within 60 days of the date hereof, plus options to purchase 220,062 shares
of Common Stock which will be exercisable within 60 days. Does not include
options to purchase 251,187 shares of Common Stock not exercisable within
60 days of the date hereof, and options to purchase 470,063 shares of
Common Stock not exercisable within 60 days..
15 Includes options to purchase 29,938 shares of Common Stock exercisable
within 60 days of the date hereof, plus options to purchase 220,062 shares
of Common Stock which will be exercisable within 60 days. Does not include
options to purchase 29,937 shares of Common Stock not exercisable within
60 days of the date hereof, and options to purchase 470,063 shares of
Common Stock not exercisable within 60 days of the date hereof.
16 Includes options to purchase 57,500 shares of Common Stock exercisable
within 60 days of the date hereof. Does not include options to purchase
50,000 shares of Common Stock not exercisable within 60 days of the date
hereof.
17 Does not include options to purchase 50,000 shares of Common Stock not
exercisable within 60 days of the date hereof.
18 Includes options to purchase 25,000 shares of Common Stock exercisable
within 60 days of the date hereof. Does not include options to purchase
50,000 shares of Common Stock not exercisable within 60 days of the date
hereof.
* Less than 1.0%
ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
None.
ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits.
3.1 Restated Certificate of Incorporation(1)
3.2 Restated and Amended By-Laws(1)
4.1 Underwriter's Unit Purchase Option(4)
4.2 Finder's Unit Purchase Option(4)
4.3 Warrant Agreement(4)
4.4 Form of Senior Secured Convertible Promissory Note (5)
4.5 Form of Class C common Stock Purchase Warrant(5)
4.6 Form of Class D Common Stock Purchase Warrant(5)
4.7 Revised Form of Amendment No. 1 to Warrant Agreement(7)
4.8 Revised Form of Class E Common Stock Purchase Warrant(7)
22
<PAGE>
10.1 Stock Redemption Agreement(1)
10.2 1989 Stock Option Plan(1)
10.3 Employment Agreement with Dr. Clifford M. Gross(1)
10.4 Employment Agreement with Arthur Fein(1)
10.5 Bridge Warrant(1)
10.6 Bridge Note and Related Loan Agreement(1)
10.7 Consulting Agreement with Lear Siegler Seating
Corporation(1)
10.8 Extension Agreement to Redemption Agreement (Exhibit
10.1)
10.9 Consulting Agreement dated August 1, 1988 with NRC
Resources Group, Inc.(1)
10.10 General Release of NRC Resources Group, Inc.(1)
10.11 Mortgage Note and Related Loan Agreement and
Mortgage and Security Agreement(1)
10.12 Second Extension Agreement to Redemption Agreement(4)
10.13 Merger and Acquisition Agreement with D.H. Blair &
Co., Inc.(4)
10.14 1989 Nonstatutory Stock Option Plan(2)
10.15 Consulting Agreement with D.H. Blair & Co., Inc.(4)
10.16 Consulting Agreement with Steelcase, Inc.(2)
10.17 License and Manufacturing Agreement with MicroComputer
Accessories, Inc.(4)
10.18 Employment Agreement with Cynthia Roth(4)
10.19 Employment Agreement with Kenneth Goodman(4)
10.20 Form of Employment Agreement with Ava Stern(4)
10.21 Form of Employment Agreement with William G. Sirois(4)
10.22 Lease of Premises at 1800 Walt Whitman Road,
Melville, New York(4)
10.23 Consulting Agreement dated as of February 1, 1990, with NRC
Resources Group, Inc.(4)
10.24 Underwriting Agreement (for IPO) with D.H. Blair & Co., Inc.(4)
10.25 Securities Purchase Agreement dated June 25, 1991, among the
Company, the Purchasers and D.H. Blair & Co., Inc.(5)
10.26 Security Agreement dated as of June 25, 1991 between the Company
and D.H. Blair & Co., Inc., as Purchasers' Representative(5)
10.29 Employment Agreement dated as of June 20, 1991 between David A.
Deutsch and the Company(5)
10.30 Letter of Understanding between Kenneth A. Goodman and the
Company(5)
10.31 Employment Agreement dated as of August 1, 1991 between Joel Sher
and the Company(5)
10.32 Amendment to 1989 Stock Option Plan(5)
10.33 Distributor Agreement with Techexport, Inc.(3)
10.34 Partnership Agreement dated December 28, 1992, for Ergonomic
Solutions Group (ESG)(8)
10.35 License Agreement dated December 28, 1992, between the Company and
ESG(8)
10.36 Development and Licensing Agreement dated March 5, 1993, between
the Company and McCord Winn Textron, Inc.(8)
10.37 Agreement dated August 22, 1992, between the Company and PT
Industry Pesawat Terbang Nusantara (IPTN)(8)
10.38 Further Amendments to 1989 Stock Option Plan(8)
10.39 Amendment to Development and Licensing Agreement dated October 27,
1993, between the Company and McCord Winn Textron.(10)
10.40 Investors Consulting Agreement with Strategic Growth International
Inc.(9)
10.41 Agreement dated December 22, 1993 between the Company and PT
Industri Pesawat Terbank Nusantara (IPTN)(9)
23
<PAGE>
10.42 Agreement dated September 29, 1993, between the Company, McCord
Winn Textron, Inc. and Lear Seating Company.(9)
10.43 Development and Licensing Agreement dated January 4, 1994, between
the Company and Reebok International Ltd.(9)
10.44 Development and License Agreement dated September 28, 1994,
between the Company and Lumex, Inc.(11)
10.45 Employment Agreement dated October 13, 1994, between Michael
Strauss and the Company 10)
10.46 Letter Agreement dated February 15, 1996, between the Company and
McCord Winn Textron, Inc. to extend the Development and License
Agreement dated March 5, 1993 (14)
10.47 Amendment to Employment Agreement between Michael Strauss and the
Company(13)
10.48 1995 Stock Option Plan(13)
10.49 Amendment letter of agreement dated August 15, 1996 between the
Company and McCord Winn Textron, Inc.(15)
10.50 Letter of agreement terminating the September 28, 1994,
Development and License Agreement between the Company and Lumex,
Inc.(15)
10.51 Letter of Agreement with Josephberg & Grosz to provide the Company
investment banking services(15)
10.52 Stock Purchase Agreement between the Company and the owners of
Drew Shoe Corporation(15)
21.00 Subsidiaries of the Company (12)
24(a) Consent of Ernst & Young, LLP.
24(b) Consent of J.H. Cohn LLP
27 Financial Data Schedule
- ----------
(1) Filed as an Exhibit to Registrant's Registration Statement on Form S-18
(file no. 33-31282) and incorporated herein by reference thereto.
(2) Filed as an Exhibit to Registrant's Annual Report on Form 10-K for the
fiscal year ended December 31, 1989 (file no. 0-18109) and incorporated
herein by reference thereto.
(3) Filed as an Exhibit to the Registrant's Annual Report on Form 10-K for the
fiscal year ended December 31, 1991 (file no. 0-18109) and incorporated
herein by reference thereto.
(4) Filed as an Exhibit to Registrant's Registration Statement on Form S-1
(file no. 33-38204) and incorporated herein by reference thereto.
(5) Filed as an Exhibit to Post Effective Amendment No. 1 to Registrant's
Registration Statement on Form S-1 (file no. 33-38204) and incorporated
herein by reference thereto.
(6) Filed as an Exhibit to Post Effective Amendment No. 2 to Registrant's
Registration Statement on Form S-1 (file no. 33-38204) and incorporated
herein by reference thereto.
(7) Filed as an Exhibit to Post-Effective Amendment No. 3 to Registrant's
Registration Statement on Form S-1 (file no. 33-38204) and incorporated
herein by reference thereto.
(8) Filed as an Exhibit to Registrant's Annual Report on Form 10-KSB for the
fiscal year ended December 31, 1992 (file no. 0-18109) and incorporated
herein by reference thereto.
(9) Filed as an Exhibit to Registrant's Annual Report on Form 10-KSB for the
fiscal year ended December 31, 1993 (file no. 0-18109) and incorporated by
reference thereto.
(10) Filed as an Exhibit to Registrant's Form 10-QSB/A filed December 5, 1994
amending the Form 10-QSB for quarterly period ended September 30, 1994
(file no. 0-18109) and incorporated by reference thereto.
(11) Filed as an Exhibit to Registrant's Form 10-QSB/A for the fiscal year
ended December 31, 1993 (file no. 0-18109) and incorporated by reference
thereto.
(12) Filed as an Exhibit to Registrant's Form 10-KSB for the fiscal year ended
December 31, 1994 (file no. 0-18109) and incorporated by reference
thereto.
24
<PAGE>
(13) Filed as an Exhibit to Registrant's Form 10-QSB for the quarter ended June
30, 1995 (file no. 0-18109) and incorporated by reference thereto.
(14) Filed as an Exhibit to Registrant's Form 10-KSB for the fiscal year ended
December 31, 1995 (file no. 0-18109) and incorporated by reference
thereto.
(15) Filed as an Exhibit to Registrant's Form 10-KSB for the fiscal year ended
December 31, 1996 (file no. 0-18109) and incorporated by reference
thereto.
(b) Reports on Form 8-K
During the fourth quarter of the period covered by this
Report, the Company filed a report on Form 8-K/A to report the
following events:
1 The acquisition of Drew Shoe Corporation ("Drew Shoe")
and to provide the audited financial information and
unaudited pro-forma information required and to disclose
Drew Shoe's entering into a bank credit facility as
described therein.
2 2 The recent sale of $1.2 million of preferred stock of
its subsidiary BCA Services, Inc. which are convertible
into the common stock of the Company as described
therein.
3 3 The acquisition financing totaling $6,000,000 of
10%/13% Convertible Notes and warrants. The Convertible
Notes are convertible into 7.5 million shares of common
stock of the Company at $0.80 per share, subject to
antidilution provisions. The warrants are exercisable
into 2.4 million shares of the Company's common stock at
$1.75 per share. The acquisition financing contains
certain covenants and other matters that are further
described therein.
4 4 Option grants to purchase approximately 2,070,000
shares of the Company's common stock.
5 5 Changes in Directors and the addition of a Vice
President - Finance.
6 6 Revisions to the terms of the Company's Class B and
Class E warrants as a result of the operation of the
anti-dilution provisions of underlying warrant
agreements in respect of the acquisition financing.
7 7 Shares, warrants and options issued in connection with
the acquisition of Drew and related acquisition
financing.
AVAILABLE INFORMATION
Registrant will furnish any exhibits listed but not contained herein to
any beneficial owner of its securities upon receipt of a written request from
such person. Requests should be directed to Shareholder Relations Department,
BCAM International, Inc., 1800 Walt Whitman Road, Melville, New York 11747.
25
<PAGE>
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
has caused this report to be signed on its behalf by the undersigned, thereto
duly authorized.
BCAM International, Inc.
By: /s/ Michael Strauss
---------------------------------------------
Michael Strauss
Chairman of the Board of Directors
Chief Executive Officer
(Principal Executive Officer)
Date: April 20, 1998
By: /s/ Kenneth C. Riscica
---------------------------------------------
Kenneth C. Riscica
Vice President - Finance,
Chief Financial Officer, Treasurer
and Secretary
(Principal Financial and Accounting Officer)
Date: April 20, 1998
26
<PAGE>
In accordance with the Exchange Act, this report has been signed below by
the following persons on behalf of the registrant and in the capacities and on
the dates indicated.
/s/ Michael Strauss Chairman of the Board April 15, 1998
- ---------------------------- of Directors
Michael Strauss and Chief Executive Officer
(Principal Executive Officer)
/s/ Robert P. Wong Director, Vice Chairman and April 15, 1998
- ---------------------------- Chief Technology Officer
Robert P. Wong
/s/ Norman B Wright Director, Vice Chairman, April 15, 1998
- ---------------------------- President and Chief
Norman B. Wright Executive Officer,
HumanCAD(R) Systems
/s/ Joel L. Gold Director April 15, 1998
- ----------------------------
Joel L. Gold
/s/ Glenn F. Santmire Director April 15, 1998
- ----------------------------
Glenn F. Santmire
/s/ Mark L Plaumann Director April 15, 1998
- ----------------------------
Mark L Plaumann
/s/ Stephen Savitsky Director April 15, 1998
- ----------------------------
Stephen Savitsky
27
Exhibit 24(a)
Consent of Independent Auditors
We consent to the incorporation by reference in the Registration Statement (Form
S-3 No. 333-34969) of BCAM International, Inc. and in the related Prospectus of
our report dated April 20, 1998, with respect to the consolidated financial
statements of BCAM International, Inc. included in the Annual
Report (Form 1O-KSB) for the year ended December 31, 1997.
/s/ Ernst & Young LLP
Melville, New York
April 20, 1998
Exhibit 24(b)
CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS
We consent to the incorporation by reference in the Registration Statement on
Form S-3 (No. 333-34969) of BCAM International, Inc. of our report, dated
September 26, 1997, on the statements of operations and cash flows of Drew Shoe
Corporation for the year ended December 31, 1996 which appear elsewhere in this
Annual Report on Form 10-KSB of BCAM International, Inc. for the year ended
December 31, 1997.
/s/ J. H. COHN LLP
Roseland, New Jersey
April 20, 1998
<TABLE> <S> <C>
<ARTICLE> 5
<RESTATED>
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> DEC-31-1997
<CASH> 1,594,000
<SECURITIES> 0
<RECEIVABLES> 1,704,000
<ALLOWANCES> 120,000
<INVENTORY> 6,278,000
<CURRENT-ASSETS> 9,914,000
<PP&E> 3,801,000
<DEPRECIATION> (832,000)
<TOTAL-ASSETS> 14,177,000
<CURRENT-LIABILITIES> 3,198,000
<BONDS> 0
0
0
<COMMON> 182,000
<OTHER-SE> 1,912,000
<TOTAL-LIABILITY-AND-EQUITY> 14,177,000
<SALES> 3,959,000
<TOTAL-REVENUES> 3,959,000
<CGS> 2,330,000
<TOTAL-COSTS> 2,330,000
<OTHER-EXPENSES> 3,313,000
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 2,976,000
<INCOME-PRETAX> 0
<INCOME-TAX> 0
<INCOME-CONTINUING> (4,660,000)
<DISCONTINUED> (1,376,000)
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (6,036,000)
<EPS-PRIMARY> (.38)
<EPS-DILUTED> (.38)
</TABLE>
